[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 58 of about 58
1. Roos FC, Roberts AM, Hwang II, Moriyama EH, Evans AJ, Sybingco S, Watson IR, Carneiro LA, Gedye C, Girardin SE, Ailles LE, Jewett MA, Milosevic M, Wilson BC, Bell JC, Der SD, Ohh M: Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med; 2010 Jul;2(7):275-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.
  • Inactivation of NF-kappaB attenuates encephalomyocarditis virus (EMCV) virulence by triggering rapid apoptosis of infected cells, thereby pre-emptively limiting viral replication.
  • Notably, intratumoural EMCV treatment of CCRCC in a murine xenograft model rapidly regresses tumour growth.
  • These findings provide compelling pre-clinical evidence for the usage of EMCV in the treatment of CCRCC and potentially other tumours with elevated HIF/NF-kappaB-survival signature.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Nov 21;24(52):7802-16 [16299539.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7636-9 [16299525.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6884-94 [16396835.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2555-62 [16638865.001]
  • [Cites] J Virol. 2006 Nov;80(21):10712-23 [16928739.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34096-103 [16980297.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):157-69 [17060462.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):15-27 [17936701.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):83-9 [18043261.001]
  • [Cites] Curr Top Microbiol Immunol. 2009;330:111-27 [19203107.001]
  • [Cites] Curr Opin Urol. 2009 Sep;19(5):447-53 [19571757.001]
  • [Cites] EMBO Mol Med. 2009 Apr;1(1):66-78 [20049704.001]
  • [Cites] Ann Surg Oncol. 2001 Sep;8(8):651-7 [11569780.001]
  • [Cites] J Virol. 2001 Dec;75(23):11621-9 [11689644.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Sep 20;297(2):224-31 [12237106.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):938-50 [12459732.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3572-9 [12458215.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1203-8 [12538858.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4003-8 [12873998.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):263-75 [14585354.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7076-80 [14612498.001]
  • [Cites] Methods Mol Med. 2004;88:111-9 [14634222.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):214-23 [14712306.001]
  • [Cites] Curr Gene Ther. 2004 Mar;4(1):15-31 [15032611.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):33-43 [15261140.001]
  • [Cites] FEBS Lett. 2004 Jul 30;571(1-3):50-4 [15280016.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] J Virol. 1984 Nov;52(2):664-71 [6492257.001]
  • [Cites] J Gen Virol. 1990 Nov;71 ( Pt 11):2761-7 [2254756.001]
  • [Cites] Cell. 1992 May 15;69(4):597-604 [1339309.001]
  • [Cites] J Virol. 1992 Sep;66(9):5525-33 [1501287.001]
  • [Cites] Annu Rev Immunol. 1994;12:141-79 [8011280.001]
  • [Cites] Cell. 1995 Jan 27;80(2):321-30 [7834752.001]
  • [Cites] Curr Opin Genet Dev. 1995 Feb;5(1):105-11 [7749317.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1885-8 [7569933.001]
  • [Cites] J Virol. 1995 Dec;69(12):7688-98 [7494278.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):529-35 [8637709.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] Science. 1996 Nov 1;274(5288):784-7 [8864119.001]
  • [Cites] Science. 1996 Nov 1;274(5288):787-9 [8864120.001]
  • [Cites] J Virol. 1997 Mar;71(3):1739-46 [9032302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1172-6 [9037025.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] J Virol. 1998 Jul;72(7):5654-60 [9621024.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] J Natl Cancer Inst. 1949 Oct;10(2):225-53, incl 8 pl [15393709.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] Drug Discov Today. 2005 Jun 15;10(12):847-55 [15970267.001]
  • [Cites] J Virol. 2005 Aug;79(16):10226-36 [16051816.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(17):7546-56 [16107702.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • (PMID = 20623734.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / NF-kappa B; 0 / RNA, Small Interfering; 0 / endothelial PAS domain-containing protein 1; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ PMC3377327
  •  go-up   go-down


2. Kishimoto C, Takada H, Kawamata H, Umatake M, Ochiai H: Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines. J Pharmacol Exp Ther; 2001 Nov;299(2):645-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines.
  • We have previously shown that immunoglobulin therapy suppressed murine coxsackievirus B3 myocarditis.
  • In the present study, we examined the effects of immunoglobulin upon murine myocarditis induced by encephalomyocarditis virus, which is not pathogenic to humans.
  • Antiviral activity of immunoglobulin (Venilon) against encephalomyocarditis virus could not be detected in vitro.
  • The production of cytokines was decreased in virus-infected macrophages by the treatment of immunoglobulin in vitro.
  • Immunoglobulin administration suppressed the development of myocardial necrosis with T-lymphocyte infiltrates in mice not only in the acute viremic but in the chronic aviremic stages concomitantly associated with the reduction of inflammatory cytokines, i.e., tumor necrosis factor-alpha, interferon-gamma, macrophage inflammatory protein-2, and interleukin-6.
  • Taken together, immunoglobulin therapy could have the potential to prevent congestive heart failure.
  • [MeSH-major] Cardiovirus Infections / therapy. Cytokines / biosynthesis. Encephalomyocarditis virus. Heart Failure / prevention & control. Immunization, Passive
  • [MeSH-minor] Animals. Cell Line. Mice. Myocardium / pathology. Organ Size / drug effects

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11602677.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


3. Tadić A, Gorbulev S, Dahmen N, Hiemke C, Braus DF, Röschke J, van Calker D, Wachtlin D, Kronfeld K, Gorbauch T, Seibert-Grafe M, Lieb K, EMC Study Group: Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial. Trials; 2010 Feb 26;11:21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.
  • BACKGROUND: In major depressive disorder (MDD), the traditional belief of a delayed onset of antidepressants' effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks before medication change in case of insufficient outcome.
  • Post hoc analyses of clinical trials, however, have shown that improvement usually occurs within the first 10-14 days of treatment and that such early improvement (Hamilton Depression Rating Scale [HAMD] decrease >or=20%) has a substantial predictive value for final treatment outcome.
  • Even more important, non-improvement (HAMD decrease <20%) after 14 days of treatment was found to be highly predictive for a poor final treatment outcome.
  • METHODS/DESIGN: The EMC trial is a phase IV, multi-centre, multi-step, randomized, observer-blinded, actively controlled parallel-group clinical trial to investigate for the first time prospectively, whether non-improvers after 14 days of antidepressant treatment with an early medication change (EMC) are more likely to attain remission (HAMD-17 <or=7) on treatment day 56 compared to patients treated according to current guideline recommendation (treatment as usual; TAU).
  • In level 1 of the EMC trial, non-improvers after 14 days of antidepressant treatment will be randomised to an EMC strategy or TAU.
  • The EMC strategy for this study schedules a first medication change on day 15; in case of non-improvement between days 15-28, a second medication change will be performed.
  • TAU schedules the first medication change after 28 days in case of non-response (HAMD-17 decrease <50%).
  • In levels 2 and 3, EMC strategies will be compared with TAU strategies in improvers on day 14, who experience a stagnation of improvement during the course of treatment.
  • DISCUSSION: If the EMC strategies lead to significantly more remitters, changes of clinical practice, guidelines for the treatment of MDD as well as research settings can be expected.
  • [MeSH-major] Antidepressive Agents / administration & dosage. Depressive Disorder, Major / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Germany. Guideline Adherence. Humans. Practice Guidelines as Topic. Prospective Studies. Psychiatric Status Rating Scales. Research Design. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Affect Disord. 2010 Jan;120(1-3):86-93 [19428118.001]
  • [Cites] Pharmacopsychiatry. 2004 Nov;37(6):243-65 [15551191.001]
  • [Cites] Lancet. 2009 Feb 28;373(9665):746-58 [19185342.001]
  • [Cites] J Psychiatr Res. 2008 Oct;42(14):1176-84 [18348888.001]
  • [Cites] Schizophr Res. 2008 Apr;101(1-3):312-9 [18308513.001]
  • [Cites] PLoS Med. 2008 Feb;5(2):e45 [18303940.001]
  • [Cites] Curr Psychiatry Rep. 2007 Dec;9(6):449-59 [18221624.001]
  • [Cites] N Engl J Med. 2008 Jan 17;358(3):252-60 [18199864.001]
  • [Cites] Int Clin Psychopharmacol. 2007 Nov;22(6):323-9 [17917550.001]
  • [Cites] J Clin Psychiatry. 2007 Aug;68(8):1195-205 [17854243.001]
  • [Cites] J Clin Psychiatry. 2007 Jun;68(6):935-40 [17592920.001]
  • [Cites] World J Biol Psychiatry. 2007;8(2):67-104 [17455102.001]
  • [Cites] J Clin Psychiatry. 2007 Mar;68(3):352-60 [17388703.001]
  • [Cites] J Clin Psychiatry. 2006 Dec;67(12):1836-55 [17194261.001]
  • [Cites] PLoS Med. 2006 Nov;3(11):e442 [17132052.001]
  • [Cites] Arch Gen Psychiatry. 2006 Nov;63(11):1217-23 [17088502.001]
  • [Cites] J Ment Health Policy Econ. 2006 Jun;9(2):87-98 [17007486.001]
  • [Cites] J Clin Psychopharmacol. 2006 Feb;26(1):56-60 [16415707.001]
  • [Cites] N Engl J Med. 2006 Mar 23;354(12):1231-42 [16554525.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):387-400 [15868067.001]
  • [Cites] Ann Intern Med. 2005 Sep 20;143(6):415-26 [16172440.001]
  • [Cites] J Clin Psychiatry. 2005 Feb;66(2):148-58 [15704999.001]
  • [Cites] Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45 [10767867.001]
  • [Cites] Am J Psychiatry. 2000 Sep;157(9):1423-8 [10964858.001]
  • [Cites] J Clin Psychiatry. 2002 Apr;63(4):331-6 [12000207.001]
  • [Cites] J Clin Psychiatry. 2002 Sep;63(9):782-90 [12363118.001]
  • [Cites] J Clin Psychiatry. 2003 Apr;64(4):413-20 [12716243.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3095-105 [12813115.001]
  • [Cites] J Clin Psychiatry. 2003 Dec;64(12):1465-75 [14728109.001]
  • [Cites] Neuropsychopharmacology. 2004 Mar;29(3):566-79 [14627997.001]
  • [Cites] Acta Psychiatr Scand Suppl. 2004;(420):21-7 [15128384.001]
  • [Cites] J Clin Psychiatry. 2004 Sep;65(9):1190-6 [15367045.001]
  • [Cites] Br J Soc Clin Psychol. 1967 Dec;6(4):278-96 [6080235.001]
  • [Cites] Arch Gen Psychiatry. 1984 Aug;41(8):782-6 [6378117.001]
  • [Cites] Arch Gen Psychiatry. 1987 Mar;44(3):259-64 [3548638.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1987;334:1-100 [2887090.001]
  • [Cites] Arch Gen Psychiatry. 1991 Sep;48(9):851-5 [1929776.001]
  • [Cites] J Clin Psychiatry. 2009 Mar;70(3):344-53 [19254516.001]
  • (PMID = 20187947.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00974155
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents
  • [Other-IDs] NLM/ PMC2837649
  • [Investigator] Lieb K; Tadić A; Hiemke C; Dreimüller N; Baskaya O; Krannich D; Lorenz S; Bernius A; Weichert T; Lorscheider M; Wagner S; Helmreich I; Grüllich K; Ostad Haji E; Lober Y; Weichert D; Schlicht K; Gorbulev S; Wachtlin D; Kronfeld K; Friedrich-Mai P; Ehrlich A; Powaska A; Gorbauch T; Seibert-Grafe M; Tubic-Grozdanis M; Jekle C; Krämer I; Dahmen N; Gerbaulet M; Sachsenheimer D; Rutschinski A; Engel A; Schwarz K; Gehrmann U; Bader S; Schneider-Pohl B; Justi M; Thierolf HC; Röschke J; Gabriel S; Kutzer M; Dorn AP; Schmidt F; Porz S; Sand I; Röschke J; Prentice T; Hössl B; Seilheimer S; Ott S; Frank C; van Calker D; Gerber S; Gross CM; Hornig T; Schneibel R; Atmannsbacher R; Braus DF; Reiff J; Kindler C; Davis S; Eyalil T; Reynisdottir T; Ginap C; Kraus J; Kaaden S; Janzen J; Löffler N; Topaloglu C
  •  go-up   go-down


Advertisement
4. Isobe N, Suzuki M, Oda M, Tanabe S: Enzyme-modified cheese exerts inhibitory effects on allergen permeation in rats suffering from indomethacin-induced intestinal inflammation. Biosci Biotechnol Biochem; 2008 Jul;72(7):1740-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enzyme-modified cheese exerts inhibitory effects on allergen permeation in rats suffering from indomethacin-induced intestinal inflammation.
  • We have found that an enzyme-modified cheese (EMC) inhibited the permeation of allergens such as ovalbumin (OVA), using Caco-2 cells as an in vitro intestinal epithelial model.
  • In addition, NPWDQ (Asn-Pro-Trp-Asp-Gln, aa 107-111 of alphas(2)-casein) was isolated from EMC and identified as one of the responsible peptides for this inhibitory activity (Tanabe et al., J. Agric.
  • In this study, we aimed to clarify the mechanism by which NPWDQ inhibited allergen permeation in vitro, and also to evaluate the effects of EMC on allergen permeation in vivo.
  • Although the plasma OVA concentration of indomethacin-administered rats after oral OVA challenge was markedly elevated over that of normal rats, supplemental administration of EMC to the rats effectively suppressed OVA permeation.
  • These results suggest that EMC is useful for the prevention of food allergy by inhibiting allergen permeation probably by enforcing the intestinal barrier.
  • [MeSH-major] Allergens / metabolism. Caseins. Cheese / adverse effects. Enzymes / metabolism. Food Hypersensitivity / prevention & control. Inflammation / drug therapy. Peptide Fragments / pharmacology

  • MedlinePlus Health Information. consumer health - Food Allergy.
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603772.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Allergens; 0 / Caseins; 0 / Enzymes; 0 / Peptide Fragments; XXE1CET956 / Indomethacin
  •  go-up   go-down


5. Han K, Sun YJ, Shen Z, Zhang JJ, Lin F, Zhao H, Meerani S, Yao Y: Extraskeletal myxoid chondrosarcoma: a case report of complete remission by chemotherapy and review of the literature. BMJ Case Rep; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal myxoid chondrosarcoma: a case report of complete remission by chemotherapy and review of the literature.
  • Extraskeletal myxoid chondrosarcoma is a rare soft tissue sarcoma.
  • The response rate to chemotherapy has been very poor; with the exception of one reported case which showed promising results, overall results are disappointing because no significant radiologic or clinical responses have been noted with chemotherapy.
  • Here we report the case of a 15-year-old girl who presented with extraskeletal myxoid chondrosarcoma in the sacrococcygeal region which was regarded as unresectable.
  • After four cycles of chemotherapy the mass showed complete remission which has lasted >6 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22315646.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029822
  •  go-up   go-down


6. Shih WJ, Mitchell B, Magoun S, Wierzbinski B: Localization of (99m)Tc HMDP in an extraskeletal myxoid chondrosarcoma: a case report. J Nucl Med Technol; 2001 Jun;29(2):84-5
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of (99m)Tc HMDP in an extraskeletal myxoid chondrosarcoma: a case report.
  • Extraskeletal myxoid chondrosarcoma of the lower extremity is rare, and slowly progressive.
  • Despite chemotherapy, the patient died 28 mo later.
  • At autopsy, it was confirmed that he had extraskeletal myxoid chondrosarcoma of the right thigh, which had metastasized to the upper arms, left scapula, lungs, pleurae, and right lower quadrant of the abdomen.
  • The myxoid chondroid matrix, a major feature of the extraskeletal myxoid chondrosarcoma, is thought to account for the localization of the bone-imaging agent.
  • [MeSH-major] Chondrosarcoma / radionuclide imaging. Radiopharmaceuticals. Soft Tissue Neoplasms / radionuclide imaging. Technetium Tc 99m Medronate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11376100.001).
  • [ISSN] 0091-4916
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


7. Drilon AD, Popat S, Bhuchar G, D'Adamo DR, Keohan ML, Fisher C, Antonescu CR, Singer S, Brennan MF, Judson I, Maki RG: Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer; 2008 Dec 15;113(12):3364-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.
  • BACKGROUND: Extraskeletal myxoid chondrosarcoma (EMC) is a genetically distinct sarcoma with a propensity for local recurrence and metastasis despite an indolent course.
  • To the authors' knowledge, there are limited data examining chemotherapy outcomes as a guide to therapeutic decisions for unresectable disease.
  • METHODS: The clinical behavior and treatment responses of 87 patients with EMC who were seen at 2 institutions between 1975 and 2008 were examined.
  • RESULTS: The median age of the patients at the time of diagnosis was 49.5 years, with a male-to-female ratio of 2:1.
  • For patients presenting without metastases, 37% developed local recurrence (median time of 3.3 years) and 26% developed distal recurrence (median time of 3.2 years).
  • Twenty-one patients received 32 evaluable courses of chemotherapy.
  • The median time to disease progression while receiving chemotherapy was 5.2 months.
  • The best physician-assessed response to chemotherapy was stable disease for at least 6 months in 25% of patients, stable disease for <6 months in 41% of patients, and disease progression in 34% of patients.
  • CONCLUSIONS: This retrospective review highlights the poor response rate to chemotherapy and emphasizes aggressive control of localized disease as the primary approach to management.
  • Although there are biases inherent in retrospective analyses, these data provide a benchmark for time to disease progression for the study of new agents for the treatment of patients with this diagnosis.
  • [MeSH-major] Chondrosarcoma / drug therapy. Chondrosarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1999 Nov;435(5):524-30 [10592057.001]
  • [Cites] Biochem J. 2007 Jun 1;404(2):197-206 [17302560.001]
  • [Cites] Adv Anat Pathol. 2000 Mar;7(2):73-8 [10721413.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):900-8 [10955458.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jan;(382):185-90 [11153986.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6832-5 [11156374.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2076-84 [11448926.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1116-24 [11679947.001]
  • [Cites] Histopathology. 2001 Nov;39(5):514-24 [11737310.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):535-43 [11673470.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):87-94 [12049818.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):340-52 [12378528.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1285-92 [12599237.001]
  • [Cites] Bioorg Med Chem Lett. 2003 May 19;13(10):1801-4 [12729668.001]
  • [Cites] Mod Pathol. 2003 May;16(5):453-9 [12748252.001]
  • [Cites] Cytogenet Genome Res. 2002;98(4):245-8 [12826747.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415):4-18 [14612624.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):214-21 [14657948.001]
  • [Cites] Curr Opin Oncol. 2004 Jul;16(4):342-54 [15187889.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):325-8 [15188455.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):585-92 [15212958.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 15;152(2):101-7 [15262426.001]
  • [Cites] Acta Pathol Jpn. 1981 May;31(3):439-47 [7270148.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2827-30 [1451062.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):161-3 [7900708.001]
  • [Cites] Cancer Genet Cytogenet. 1995 May;81(1):33-7 [7773957.001]
  • [Cites] Chest. 1995 Jul;108(1):281-2 [7606973.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):398-402 [7635565.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Oncogene. 1999 May 27;18(21):3303-8 [10359536.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):636-50 [10366145.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1199-208 [15536069.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):453-63 [15998372.001]
  • [Cites] J Pathol. 2005 Aug;206(4):433-44 [15920699.001]
  • [Cites] Biol Pharm Bull. 2005 Sep;28(9):1603-7 [16141523.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 21;346(1):306-13 [16756948.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7599-601 [10602520.001]
  • (PMID = 18951519.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA047179-15A2; United States / NCI NIH HHS / CA / P01 CA047179-18; United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS139129; NLM/ PMC2779719
  •  go-up   go-down


8. Sonnenfeld G, Tovey M, Schellekens H, Kinney KS, Belay T, Morton DS, Austin CE, Reitman M, Fong TA, Vaughan HS: Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus. J Interferon Cytokine Res; 2001 Jul;21(7):539-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus.
  • Intraperitoneal (i.p.) injection of mice with encephalomyocarditis virus (EMCV) gives rise to a rapidly progressive fatal disease characterized by central nervous system involvement and encephalitis.
  • The primary objective of the study was to determine the efficacy of recombinant murine IFN-alpha (rMuIFN-alpha) in the treatment of mice infected with 100 LD(50) EMCV following oral, i.n., and i.p. administration at doses of 20,000 and 100,000 IU.
  • The negative controls, infection of mice with 100 LD(50) of EMCV followed by treatment with excipient via all three routes, resulted in death of nearly all mice, as expected.
  • The positive control, treatment of EMCV-infected (100 LD(50)) mice with rMuIFN-alpha via the i.p. route, was successful in protecting a significant number of mice from death compared with matched controls.
  • [MeSH-major] Antiviral Agents / administration & dosage. Antiviral Agents / adverse effects. Cardiovirus Infections / drug therapy. Encephalomyocarditis virus / drug effects. Interferon Type I / administration & dosage. Interferon Type I / adverse effects
  • [MeSH-minor] Administration, Intranasal. Administration, Oral. Animals. Drug Evaluation, Preclinical / methods. Female. Injections, Intraperitoneal. Lethal Dose 50. Mice. Random Allocation. Recombinant Proteins. Titrimetry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11506749.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon Type I; 0 / Recombinant Proteins
  •  go-up   go-down


9. Takeda A, Tsuchiya H, Mori Y, Nonomura A, Tomita K: Extraskeletal myxoid chondrosarcoma with multiple skeletal metastases. J Orthop Sci; 2000;5(2):171-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal myxoid chondrosarcoma with multiple skeletal metastases.
  • Pulmonary metastases are not unusual in extraskeletal myxoid chondrosarcoma; however, only two patients have been reported with multiple bony metastases.
  • We report here one patient with extraskeletal myxoid chondrosarcoma associated with lung and multiple bony metastases.
  • After chemotherapy, the primary lesion was resected, but lung and multiple bony metastases were found 20 months later.
  • After chemotherapy, the lung metastases were resected, and those in the vertebral bodies were treated with radiotherapy.
  • [MeSH-major] Bone Neoplasms / secondary. Chondrosarcoma / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / secondary. Femoral Neoplasms / therapy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10982652.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


10. Lefaucheur JP, Holsheimer J, Goujon C, Keravel Y, Nguyen JP: Descending volleys generated by efficacious epidural motor cortex stimulation in patients with chronic neuropathic pain. Exp Neurol; 2010 Jun;223(2):609-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidural motor cortex stimulation (EMCS) is a therapeutic option for chronic, drug-resistant neuropathic pain, but its mechanisms of action remain poorly understood.
  • In two patients with refractory hand pain successfully treated by EMCS, the presence of implanted epidural cervical electrodes for spinal cord stimulation permitted to study the descending volleys generated by EMCS in order to better appraise the neural circuits involved in EMCS effects.
  • At low-intensity, anodal monopolar EMCS generated D-waves, suggesting direct activation of corticospinal fibers, whereas cathodal EMCS generated I2-waves, suggesting transsynaptic activation of corticospinal tract.
  • The bipolar electrode configuration used in chronic EMCS to produce maximal pain relief generated mostly I3-waves.
  • This result suggests that EMCS induces analgesia by activating top-down controls originating from intracortical horizontal fibers or interneurons but not by stimulating directly the pyramidal tract.
  • The descending volleys elicited by bipolar EMCS are close to those elicited by transcranial magnetic stimulation using a coil with posteroanterior orientation.
  • Different pathways are activated by EMCS according to stimulus intensity and electrode montage and polarity.
  • Special attention should be paid to these parameters when programming EMCS for pain treatment.
  • [MeSH-major] Motor Cortex / physiology. Neuralgia / physiopathology. Neuralgia / therapy. Pyramidal Tracts / physiology. Transcranial Magnetic Stimulation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20188091.001).
  • [ISSN] 1090-2430
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Tangjitgamol S, Manusirivithaya S, Lertbutsayanukul C: Adjuvant therapy for early-stage endometrial cancer: a review. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):949-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy for early-stage endometrial cancer: a review.
  • Most patients with endometrial cancer (EMC) present their symptoms early in their course, leading to an overall favorable outcome.
  • However, some patients who are in early-stage diseases may carry some risk features that would hamper their prognoses.
  • For these early-stage diseases with high risk of recurrences, radiation therapy certainly plays a major role as an adjuvant treatment.
  • To improve the prognoses, other types of adjuvant therapy have been attempted.
  • In this review, various options of adjuvant treatment for this early-stage EMC including radiation therapy, chemotherapy, and hormonal therapy are discussed.
  • [MeSH-major] Carcinoma / therapy. Endometrial Neoplasms / therapy. Neoadjuvant Therapy / methods
  • [MeSH-minor] Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309664.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


12. Valk GD, Renders CM, Kriegsman DM, Newton KM, Twisk JW, van Eijk JT, van der Wal G, Wagner EH: Quality of care for patients with type 2 diabetes mellitus in the Netherlands and the United States: a comparison of two quality improvement programs. Health Serv Res; 2004 Aug;39(4 Pt 1):709-25
MedlinePlus Health Information. consumer health - Diabetes Type 2.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of care for patients with type 2 diabetes mellitus in the Netherlands and the United States: a comparison of two quality improvement programs.
  • STUDY SETTING: Primary care in the ExtraMural Clinic (EMC) of the Department of General Practice of the Vrije Universiteit in Amsterdam, the Netherlands, and the Group Health Cooperative (GHC), a group-model health maintenance organization (HMO) in western Washington State in the United States.
  • Only the Dutch program (EMC) included guidelines on the structure of diabetes care and a recall system.
  • DATA COLLECTION: Included were 379 EMC patients, and 2,119 GHC patients with type 2 diabetes mellitus.
  • PRINCIPAL FINDINGS: In the EMC process outcomes and glycemic control improved more than at GHC, however, GHC had better baseline measures.
  • During follow-up, intensification of pharmacotherapy was noted at both sites.
  • [MeSH-major] Diabetes Mellitus, Type 2 / therapy. Family Practice / standards. Health Maintenance Organizations / standards. Health Services Accessibility / standards. Outpatient Clinics, Hospital / standards. Quality Assurance, Health Care / organization & administration
  • [MeSH-minor] Aged. Blood Glucose / metabolism. Cohort Studies. Cultural Characteristics. Female. Health Services Needs and Demand. Humans. Longitudinal Studies. Male. Middle Aged. Netherlands. Outcome Assessment (Health Care). Patient Satisfaction / statistics & numerical data. Time Factors. Washington

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • Genetic Alliance. consumer health - Diabetes mellitus type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2001;(1):CD001481 [11279717.001]
  • [Cites] Diabetes Care. 2001 Aug;24(8):1365-70 [11473071.001]
  • [Cites] Diabet Med. 1988 Apr;5(3):275-81 [2967151.001]
  • [Cites] Health Trends. 1990;22(1):39-43 [10106791.001]
  • [Cites] Fam Pract. 1999 Aug;16(4):402-6 [10493712.001]
  • [Cites] JAMA. 1995 May 17;273(19):1503-8 [7739076.001]
  • [Cites] Diabetes Care. 1998 Sep;21(9):1432-8 [9727887.001]
  • [Cites] Eff Clin Pract. 1998 Aug-Sep;1(1):12-22 [10345254.001]
  • [Cites] JAMA. 1999 Jun 2;281(21):2005-12 [10359389.001]
  • [Cites] Br J Gen Pract. 1990 Sep;40(338):361-4 [2265001.001]
  • (PMID = 15230924.001).
  • [ISSN] 0017-9124
  • [Journal-full-title] Health services research
  • [ISO-abbreviation] Health Serv Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  • [Other-IDs] NLM/ PMC1361034
  •  go-up   go-down


13. Horta R, Barreto F, Marques M, Rebelo M, Reis JC, Lopes JM, Amarante JM: Epithelial-myoepithelial parotid carcinoma after kidney transplantation. Ecancermedicalscience; 2008;2:92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of a second malignant neoplasm (SMN) in patients who have been submitted to kidney transplantation is increasing and causes concern; parotid carcinoma is rarely reported after transplantation and may be related to long-term chemotherapy.Salivary gland carcinomas displaying exclusively myoepithelial differentiation-myoepithelial carcinomas (EMC) are rare, being less than 1% of all salivary gland tumours.
  • EMC arises most commonly in the parotid gland and usually occurs in women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22275975.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234068
  •  go-up   go-down


14. Yi JW, Park YK, Choi YM, Hong HP, Chang SG: Bulbous urethra involved in perineal extraskeletal myxoid chondrosarcoma in a child. Int J Urol; 2004 Jun;11(6):436-9
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bulbous urethra involved in perineal extraskeletal myxoid chondrosarcoma in a child.
  • Extraskeletal myxoid chondrosarcoma is a rare soft-tissue sarcoma that usually occurs in deep soft tissues, especially those of the proximal extremities and limb girdles, but is rare in children.
  • The patient was treated with surgical excision and urethroplasty followed by combination chemotherapy.
  • [MeSH-major] Chondrosarcoma / pathology. Perineum / pathology. Soft Tissue Neoplasms / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15157219.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


15. Muralidharan P, Kumar VR, Balamurugan G: Protective effect of Morinda citrifolia fruits on beta-amyloid (25-35) induced cognitive dysfunction in mice: an experimental and biochemical study. Phytother Res; 2010 Feb;24(2):252-8
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neuroprotective effect of an ethyl acetate extract of Morinda citrifolia (Rubiaceae) Linn. fruits (EMC, ethyl acetate extract of Morinda citrifolia) at doses of 200 and 400 mg/kg, p.o. was studied on beta-amyloid (25-35) peptide induced cognitive dysfunction in mice.
  • In the step-down inhibitory avoidance, EMC exhibited a significant increase in short-term memory and long-term memory (p < 0.05).
  • A significant increase (p < 0.01) in alteration of behavior was exhibited upon administration of EMC 200 and 400 mg/kg on the Y maze.
  • Exploratory parameters such as line crossings, head dipping and rearing were increased significantly in EMC treated groups in a dose-dependent manner (p < 0.05 and p < 0.01).
  • A significant reduction (p < 0.05) in acetyl cholinesterase activity was noticed in the EMC 200 and 400 mg/kg treated groups.
  • The level of monoamine oxidase-A was decreased by the administration of EMC 200 and 400 mg/kg (p < 0.05 and p < 0.01, respectively).
  • EMC at a dose of 400 mg/kg exhibited a significant increase (p < 0.01) in the levels of serotonin and dopamine.
  • Antioxidant enzymes such as superoxide dismutase, glutathione reductase, glutathione peroxidase and ascorbic acid were decreased significantly in the b-amyloid peptide injected group, whose levels were restored significantly (p < 0.01) by the administration of EMC (400 mg/kg).
  • [MeSH-major] Cognition Disorders / drug therapy. Memory, Short-Term / drug effects. Morinda / chemistry. Neuroprotective Agents / pharmacology. Plant Extracts / pharmacology
  • [MeSH-minor] Amyloid beta-Peptides. Animals. Avoidance Learning / drug effects. Dopamine / analysis. Female. Fruit / chemistry. Male. Maze Learning / drug effects. Mice. Mice, Inbred Strains. Monoamine Oxidase / analysis. Motor Activity / drug effects. Peptide Fragments. Serotonin / analysis. Toxicity Tests, Acute

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19585480.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Neuroprotective Agents; 0 / Peptide Fragments; 0 / Plant Extracts; 0 / amyloid beta-protein (25-35); 333DO1RDJY / Serotonin; EC 1.4.3.4 / Monoamine Oxidase; VTD58H1Z2X / Dopamine
  •  go-up   go-down


16. Gupta P, Bajpai SK, Chandra K, Singh KL, Tandon JS: Antiviral profile of Nyctanthes arbortristis L. against encephalitis causing viruses. Indian J Exp Biol; 2005 Dec;43(12):1156-60
Hazardous Substances Data Bank. N-BUTYL ALCOHOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ethanolic extracts, various fractions and two pure compounds isolated from the plant N. arbortris were tested against Encephalomyocarditis Virus (EMCV) and Semliki Forest Virus (SFV).
  • [MeSH-major] Encephalomyocarditis virus / drug effects. Oleaceae. Seeds. Semliki forest virus / drug effects
  • [MeSH-minor] 1-Butanol / administration & dosage. 1-Butanol / pharmacology. Administration, Oral. Alphavirus Infections / drug therapy. Alphavirus Infections / mortality. Animals. Cardiovirus Infections / drug therapy. Cardiovirus Infections / mortality. Cercopithecus aethiops. Dose-Response Relationship, Drug. Glycosides / administration & dosage. Glycosides / pharmacology. Injections, Intraperitoneal. Iridoids / administration & dosage. Iridoids / pharmacology. Mice. Phytotherapy / methods. Plant Extracts / pharmacology. Vero Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359127.001).
  • [ISSN] 0019-5189
  • [Journal-full-title] Indian journal of experimental biology
  • [ISO-abbreviation] Indian J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glycosides; 0 / Iridoids; 0 / Plant Extracts; 8PJ61P6TS3 / 1-Butanol
  •  go-up   go-down


17. Zhang J, Yamada O, Sakamoto T, Yoshida H, Araki H, Shimotohno K: Exploiting cis-acting replication elements to direct hepatitis C virus-dependent transgene expression. J Virol; 2005 May;79(10):5923-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploiting cis-acting replication elements to direct hepatitis C virus-dependent transgene expression.
  • We describe here a novel targeting gene therapy strategy to direct gene expression responsive to hepatitis C virus (HCV).
  • The goal was approached by engineering a construct containing the antisense sequence of the transgene and internal ribosome entry site of encephalomyocarditis virus flanked by 5'- and 3'-end sequences of HCV cDNA that contain cis-acting replication elements.
  • [MeSH-minor] Adenoviridae / genetics. Adenoviridae / metabolism. Cell Line. Cell Line, Transformed. Cell Survival / drug effects. Cytopathogenic Effect, Viral / drug effects. DNA Polymerase II / biosynthesis. DNA Polymerase II / genetics. Encephalomyocarditis virus / genetics. Flucytosine / pharmacology. Gene Expression Regulation, Viral. Genes, Transgenic, Suicide. Genetic Therapy / methods. Genetic Vectors. Humans. Luciferases / genetics. RNA, Small Interfering / genetics. RNA, Viral / biosynthesis. Transfection. Viral Nonstructural Proteins / antagonists & inhibitors. Viral Nonstructural Proteins / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1999 Dec;73(12):9718-25 [10559281.001]
  • [Cites] Virology. 1999 Sep 1;261(2):263-70 [10497111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5516-21 [10805807.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17710-7 [10749880.001]
  • [Cites] J Virol. 2000 Jul;74(14):6394-400 [10864650.001]
  • [Cites] J Virol. 2001 May;75(10):4633-40 [11312333.001]
  • [Cites] FEMS Microbiol Lett. 2001 Aug 21;202(2):149-56 [11520607.001]
  • [Cites] J Gen Virol. 2002 Mar;83(Pt 3):567-79 [11842252.001]
  • [Cites] Virology. 2002 Feb 1;293(1):141-50 [11853407.001]
  • [Cites] Curr Pharm Des. 2002;8(11):959-66 [11945142.001]
  • [Cites] Nat Struct Biol. 2002 May;9(5):370-4 [11927953.001]
  • [Cites] J Virol. 2002 Jun;76(11):5326-38 [11991961.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 10;293(3):993-9 [12051758.001]
  • [Cites] Nat Biotechnol. 2002 Oct;20(10):1006-10 [12244328.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38322-7 [12167642.001]
  • [Cites] J Virol. 2003 Mar;77(6):3557-68 [12610131.001]
  • [Cites] J Gen Virol. 2003 Nov;84(Pt 11):3099-104 [14573815.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Nov;47(11):3525-30 [14576112.001]
  • [Cites] J Virol. 2004 Feb;78(3):1352-66 [14722290.001]
  • [Cites] J Gen Virol. 2004 Feb;85(Pt 2):429-39 [14769901.001]
  • [Cites] Virology. 2004 Mar 1;320(1):135-43 [15003869.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):2260-6 [15155230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6547-9 [2168552.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451-5 [1848704.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5547-51 [1648221.001]
  • [Cites] Mol Microbiol. 1992 May;6(10):1335-44 [1640834.001]
  • [Cites] N Engl J Med. 1992 Dec 31;327(27):1899-905 [1280771.001]
  • [Cites] J Virol. 1993 May;67(5):2832-43 [8386278.001]
  • [Cites] Nucleic Acids Res. 1993 Jul 11;21(14):3277-80 [8341602.001]
  • [Cites] Hum Gene Ther. 1995 Aug;6(8):1055-63 [7578418.001]
  • [Cites] EMBO J. 1996 Jan 2;15(1):12-22 [8598194.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1534-42 [8657127.001]
  • [Cites] Intervirology. 1997;40(5-6):378-93 [9675642.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5A):3399-406 [9858915.001]
  • [Cites] J Virol. 1999 Feb;73(2):1535-45 [9882359.001]
  • [Cites] J Virol. 1999 Mar;73(3):2333-42 [9971816.001]
  • [Cites] Science. 1999 Jul 2;285(5424):110-3 [10390360.001]
  • [Cites] J Virol. 1999 Aug;73(8):7044-9 [10400807.001]
  • [Cites] J Virol. 1999 Sep;73(9):7694-702 [10438859.001]
  • [Cites] J Med Virol. 1999 Oct;59(2):131-4 [10459145.001]
  • [Cites] Antivir Ther. 1998;3(Suppl 3):71-81 [10726057.001]
  • (PMID = 15857978.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NS-5 protein, hepatitis C virus; 0 / RNA, Small Interfering; 0 / RNA, Viral; 0 / Viral Nonstructural Proteins; D83282DT06 / Flucytosine; EC 1.13.12.- / Luciferases; EC 2.7.7.- / DNA Polymerase II; EC 3.5.4.1 / Cytosine Deaminase
  • [Other-IDs] NLM/ PMC1091670
  •  go-up   go-down


18. Veldhuyzen Van Zanten S, Machado S, Lee J: One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther; 2003 Jun 1;17(11):1381-7
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection.
  • AIM: To compare the eradication rates of treatment with esomeprazole, metronidazole and clarithromycin (EMC) vs. omeprazole, metronidazole and clarithromycin (OMC), given for 7 days.
  • OMC treatment was followed by 3 weeks of treatment with 20 mg omeprazole alone; the EMC group received placebo.
  • The eradication of H. pylori was determined by two negative breath tests performed at least 4 and 8 weeks following the completion of treatment.
  • The success rates of EMC/placebo were 76% (144/190) by intention-to-treat and 80% (138/172) by per protocol analysis; for OMC/omeprazole, the rates were 72% (137/189) and 75% (125/167), respectively.
  • The difference between the two treatment groups was not significant.
  • Treatment was well tolerated.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Anti-Ulcer Agents / administration & dosage. Clarithromycin / administration & dosage. Helicobacter Infections / drug therapy. Helicobacter pylori. Metronidazole / administration & dosage. Omeprazole / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Double-Blind Method. Drug Administration Schedule. Drug Therapy, Combination. Esomeprazole. Female. Humans. Male. Middle Aged. Patient Compliance. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12786632.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 140QMO216E / Metronidazole; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole; N3PA6559FT / Esomeprazole
  •  go-up   go-down


19. Olson EJ, Lindgren BR, Carlson CS: Effects of long-term estrogen replacement therapy on bone turnover in periarticular tibial osteophytes in surgically postmenopausal cynomolgus monkeys. Bone; 2008 May;42(5):907-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of long-term estrogen replacement therapy on bone turnover in periarticular tibial osteophytes in surgically postmenopausal cynomolgus monkeys.
  • The aims of the present study were to assess the effects of long-term estrogen replacement therapy (ERT) on size and indices of bone turnover in periarticular osteophytes in ovariectomized cynomolgus monkeys and to compare dynamic indices of bone turnover in osteophyte bone with those of subchondral bone (SCB) and epiphyseal/metaphyseal cancellous (EMC) bone.
  • One hundred sixty-five adult female cynomolgus macaques were bilaterally ovariectomized and randomly divided into three age- and weight-matched treatment groups for a 36-month treatment period.
  • Group 1 (OVX control) received no treatment, Group 2 (SPE) received soy phytoestrogens, and Group 3 (ERT) received conjugated equine estrogens in the diet; all monkeys were labeled with calcein before necropsy.
  • A midcoronal, plastic-embedded section of the right proximal tibia from 20 randomly selected animals per treatment group was examined histologically.
  • Forty-nine of the sections (OVX control, n=16; SPE, n=16; ERT, n=17) contained lateral abaxial osteophytes, and static and dynamic histomorphometry measurements were taken from osteophyte bone, SCB from the lateral tibial plateau, and EMC bone.
  • The bone volume, trabecular number, and trabecular thickness in osteophyte bone were considerably higher than in EMC bone; whereas, trabecular separation was considerably lower in osteophyte bone.
  • In all three treatment groups, BS/BV was significantly lower in osteophyte bone vs. EMC bone and significantly higher in osteophyte bone vs. lateral SCB.
  • We conclude that osteophyte area and static and dynamic histomorphometry parameters within periarticular tibial osteophytes in ovariectomized cynomolgus monkeys are not significantly influenced by long-term ERT, but that site differences in static and dynamic bone histomorphometry parameters exist, particularly between EMC and osteophyte bone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Osteoarthritis Cartilage. 2006 May;14(5):413-7 [16442316.001]
  • [Cites] Arthritis Rheum. 2005 Oct;52(10):3152-9 [16200595.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):419-447 [11152762.001]
  • [Cites] Hum Reprod Update. 2000 Sep-Oct;6(5):419-26 [11045872.001]
  • [Cites] Bone. 2007 Aug;41(2):282-9 [17540630.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):41-7 [11231976.001]
  • [Cites] Am J Sports Med. 2002 May-Jun;30(3):414-21 [12016084.001]
  • [Cites] Arthritis Rheum. 2002 Jul;46(7):1956-64 [12124881.001]
  • [Cites] J Bone Miner Res. 2004 May;19(5):823-9 [15068506.001]
  • [Cites] Clin Orthop Relat Res. 1969 Jan-Feb;62:37-47 [4975461.001]
  • [Cites] Lab Anim. 1970 Apr;4(1):113-24 [5005918.001]
  • [Cites] Ann Rheum Dis. 1975 Feb;34(1):12-25 [1124952.001]
  • [Cites] J Bone Miner Res. 1987 Dec;2(6):595-610 [3455637.001]
  • [Cites] J Orthop Res. 1994 May;12(3):331-9 [8207586.001]
  • [Cites] J Bone Miner Res. 1994 Apr;9(4):527-40 [8030441.001]
  • [Cites] Ann Rheum Dis. 1998 Jul;57(7):401-7 [9797566.001]
  • [Cites] Osteoarthritis Cartilage. 2007 Mar;15(3):237-44 [17204437.001]
  • (PMID = 18291743.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / R01 RR014099; United States / NCRR NIH HHS / RR / RR014099-13; United States / NIH HHS / OD / T32 OD010993; United States / NCRR NIH HHS / RR / R01 RR014099-13; United States / NCRR NIH HHS / RR / RR18719; United States / NCRR NIH HHS / RR / RR14099; United States / NCRR NIH HHS / RR / T32 RR018719; United States / NCRR NIH HHS / RR / RR018719-03; United States / NCRR NIH HHS / RR / T32 RR018719-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Estrogens; 0 / Estrogens, Conjugated (USP); 0 / Phytoestrogens
  • [Other-IDs] NLM/ NIHMS47964; NLM/ PMC2435307
  •  go-up   go-down


20. Benvenuti E, Cecchi F, Colombini A, Gori G: Extradural motor cortex stimulation as a method to treat advanced Parkinson's disease: new perspectives in geriatric medicine. Aging Clin Exp Res; 2006 Aug;18(4):347-8
MedlinePlus Health Information. consumer health - Parkinson's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Motor fluctuations not controlled by pharmacological therapy are often encountered in long-term Parkinson's disease (PD).
  • Neurosurgery treatment represented by deep brain stimulation (DBS) was considered a valid alternative to pharmacological treatment.
  • Recently it has been suggested that extradural motor cortex stimulation (EMCS) could be a valid cost-effective alternative to DBS to control motor symptoms in patients affected by Parkinson's disease.
  • The relevant non-invasive surgical technique makes this treatment particularly indicated in geriatric patients.
  • Brain atrophy, cognitive impairment, psychiatric symptoms are not an absolute contraindication to the treatment.
  • We submitted to EMCS an outpatient afferent to our geriatric department, a woman 68 yrs old.
  • If our findings will be confirmed in larger series, a new dimension will be added to the treatment of PD.
  • [MeSH-major] Electric Stimulation Therapy / methods. Motor Cortex / physiology. Parkinson Disease / physiopathology. Parkinson Disease / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Geriatrics / methods. Humans. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Severity of Illness Index. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063072.001).
  • [ISSN] 1594-0667
  • [Journal-full-title] Aging clinical and experimental research
  • [ISO-abbreviation] Aging Clin Exp Res
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  •  go-up   go-down


21. Xiao J, Shimada M, Liu W, Hu D, Matsumori A: Anti-inflammatory effects of eplerenone on viral myocarditis. Eur J Heart Fail; 2009 Apr;11(4):349-53
Hazardous Substances Data Bank. SPIRONOLACTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Four-week-old inbred male DBA/2 mice were inoculated intraperitoneally with 10 plaque-forming units (pfu) of the encephalomyocarditis (EMC) virus.
  • Survival at 28 days was significantly higher in the mice which started eplerenone treatment on day 0 (35 vs. 15% in controls, each n = 40, P < 0.05).
  • Gene expression of mouse mast cell proteases-4 and -5, matrix metalloproteinase-9, and type I procollagen on day 6 after EMC virus inoculation was significantly decreased in the hearts of eplerenone-treated mice.
  • [MeSH-major] Cardiovirus Infections / drug therapy. Encephalomyocarditis virus / pathogenicity. Myocarditis / drug therapy. Spironolactone / analogs & derivatives
  • [MeSH-minor] Animals. DNA, Viral / analysis. Disease Models, Animal. Male. Mice. Mice, Inbred DBA. Mineralocorticoid Receptor Antagonists / therapeutic use. Myocardium / pathology. Polymerase Chain Reaction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213804.001).
  • [ISSN] 1388-9842
  • [Journal-full-title] European journal of heart failure
  • [ISO-abbreviation] Eur. J. Heart Fail.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Mineralocorticoid Receptor Antagonists; 27O7W4T232 / Spironolactone; 6995V82D0B / eplerenone
  •  go-up   go-down


22. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G: Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther; 2004 Dec;9(6):1003-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
  • The results showed that SARS-CoV grown in Vero cells is moderately sensitive to IFN-beta and only weakly sensitive to IFN-alpha and IFN-gamma, in comparison to other IFN-sensitive viruses, such as those for encephalomyocarditis, vesicular stomatitis and Newcastle disease.
  • [MeSH-major] Interferon Type I / pharmacology. Interferon-gamma / pharmacology. SARS Virus / drug effects. Virus Replication / drug effects
  • [MeSH-minor] Animals. Cercopithecus aethiops. Drug Synergism. GTP-Binding Proteins / genetics. GTP-Binding Proteins / metabolism. Humans. Myxovirus Resistance Proteins. Recombinant Proteins / pharmacology. Vero Cells

  • Genetic Alliance. consumer health - SARS.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15651759.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Type I; 0 / MX1 protein, human; 0 / Myxovirus Resistance Proteins; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma; EC 3.6.1.- / GTP-Binding Proteins
  •  go-up   go-down


23. Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O, Muftuoglu E: A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab. J Thromb Thrombolysis; 2009 Feb;27(2):220-2
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current treatment options of essential mixed cryoglobulinemia (EMC); include immunosuppressive approaches, such as corticosteroids, cyclophosphamide, plasma exchange, other cytotoxic drugs in moderate to severe manifestations.
  • Although, the published evidence for treatment of EMC with rituximab is restricted to case reports, which have shown positive results.
  • Several diseases include lymphoproliferative and myeloproliferative disorders, solid tumors, immunological disorders, cardiovascular disorders and some drugs associated with acquired von Willebrand disease (avWD).
  • In this present case report, we showed the efficacy of rituximab in a 21-year-old female patient, suffered from neuropathy and arthralgia related with EMC, and developed avWD, presented with mucosal bleeding associated with CG. von Willebrand factor activity of our patient also increased with controlling the underlying disease, EMC by rituximab.
  • This case demonstrate that rituximab may be an effective treatment option in EMC and avWD mainly related to CG.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Cryoglobulinemia / complications. Cryoglobulinemia / drug therapy. von Willebrand Diseases / drug therapy

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • Genetic Alliance. consumer health - Von Willebrand Disease.
  • Genetic Alliance. consumer health - Willebrand disease, acquired.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:158-64 [18024624.001]
  • [Cites] Clin Immunol. 2007 Oct;125(1):30-3 [17692572.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):410-1 [15657071.001]
  • [Cites] Ann Rheum Dis. 2002 Oct;61(10):922-4 [12228164.001]
  • [Cites] Am J Hematol. 2007 May;82(5):368-75 [17133419.001]
  • [Cites] Rheumatology (Oxford). 2007 Feb;46(2):366-7 [17127691.001]
  • [Cites] Dig Liver Dis. 2007 Sep;39 Suppl 1:S122-8 [17936213.001]
  • [Cites] Braz J Infect Dis. 2007 Feb;11(1):174-5 [17625752.001]
  • (PMID = 18193394.001).
  • [ISSN] 1573-742X
  • [Journal-full-title] Journal of thrombosis and thrombolysis
  • [ISO-abbreviation] J. Thromb. Thrombolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / von Willebrand Factor; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


24. Gao X, Peng L, Adhikari CM, Lin J, Zuo Z: Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail; 2007 Apr;13(3):170-7
Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: We randomized 116 consecutive patients with CHF into placebo control group (n = 58) and spironolactone group (20 mg daily, n = 58) in addition to conventional therapy.
  • Plasma magnesium concentration (PMC), erythrocyte magnesium concentration (EMC), and erythrocyte magnesium efflux were not different between the 2 groups of patients before treatment.
  • Compared with control patients, patients treated with spironolactone for 6 months had increased PMC and EMC and decreased erythrocyte magnesium efflux.
  • Patients on spironolactone therapy also had a marked decrease of 24-hour mean heart rate, ventricular and atrial premature beats, and the risk of atrial fibrillation/flutter.
  • Pooled data from the 116 patients showed that patients with a higher EMC or a lower sodium-dependent erythrocyte magnesium efflux had a slower heart rate, fewer ventricular premature beats, and a lower risk of atrial fibrillation/flutter.
  • [MeSH-major] Arrhythmias, Cardiac / prevention & control. Heart Failure / complications. Heart Failure / drug therapy. Magnesium Deficiency / complications. Magnesium Deficiency / drug therapy. Mineralocorticoid Receptor Antagonists / therapeutic use. Spironolactone / therapeutic use
  • [MeSH-minor] Dose-Response Relationship, Drug. Double-Blind Method. Erythrocytes / metabolism. Exercise Tolerance / drug effects. Female. Heart Function Tests / drug effects. Homeostasis / drug effects. Humans. Magnesium / blood. Male. Middle Aged. Potassium / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448413.001).
  • [ISSN] 1532-8414
  • [Journal-full-title] Journal of cardiac failure
  • [ISO-abbreviation] J. Card. Fail.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mineralocorticoid Receptor Antagonists; 27O7W4T232 / Spironolactone; I38ZP9992A / Magnesium; RWP5GA015D / Potassium
  •  go-up   go-down


25. Graeser R, Chung DE, Esser N, Moor S, Schächtele C, Unger C, Kratz F: Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int J Cancer; 2008 Mar 1;122(5):1145-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have recently investigated a macromolecular prodrug strategy for improved cancer chemotherapy based on 2 features: (i) rapid and selective binding of thiol-reactive prodrugs to the cysteine-34 position of endogenous albumin after intravenous administration, and (ii) enzymatic release of the albumin-bound drug at the tumor site (Mansour et al., Cancer Res 2003, 63, 4062-4066).
  • In this work, we describe an albumin-binding prodrug, EMC-Arg-Ser-Ser-Tyr-Tyr--Ser-Arg-DOXO [EMC: epsilon-Maleimidocaproic acid; DOXO = doxorubicin; X = amino acid] that is cleaved by PSA.
  • Incubation studies with PSA and tumor homogenates from PSA-positive tumors (LNCaP) demonstrated that the albumin-bound form of the prodrug was efficiently cleaved by PSA at the P(1)-P' (1) scissile bond releasing the doxorubicin dipeptide H-Ser-Arg-DOXO, which was further degraded to doxorubicin as the final cleavage product.
  • In cell culture experiments, the prodrug was approximately 100-fold less active against LNCaP cells than the free drug.
  • Doxorubicin treatment at a dose of 2 x 4 mg/kg caused significant weight loss and mortality (-25%), and did not result in a significant antitumor response at the end of the experiment.
  • [MeSH-major] Albumins / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / therapeutic use. Prodrugs / chemical synthesis. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17973264.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / Antibiotics, Antineoplastic; 0 / Prodrugs; 80168379AG / Doxorubicin; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


26. Ham KD, Carlson CS: Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J Bone Miner Res; 2004 May;19(5):823-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys.
  • INTRODUCTION: Estrogen replacement therapy (ERT) decreases the risk of osteoporosis and osteoarthritis (OA) in postmenopausal women and has been shown to have direct effects on cells of the bone and cartilage.
  • At necropsy, the proximal tibias of 20 randomly selected animals from each treatment group were embedded in bioplastic and sectioned.
  • Areas and labels were measured in a carefully defined region of the SC bone and epiphyseal/metaphyseal cancellous (EMC) bone, and derived dynamic and static indices were compared between the SC and EMC bone and among the three treatment groups.
  • Student's t-tests and ANOVA were used to compare the data.
  • RESULTS AND CONCLUSIONS: In both the SC and EMC bone, most of the values for the dynamic indices were highest in the OVX control group, intermediate in the SPE group, and lowest in the ERT group.
  • The mineralizing surface, double-labeled surface, and bone formation rate (surface referent) were significantly higher in the SC bone compared with the EMC bone in the OVX control group.
  • In conclusion, the bone turnover indices were higher in the SC bone compared with the EMC bone, and ERT decreased these indices in both sites.
  • [MeSH-major] Bone Remodeling / drug effects. Epiphyses / metabolism. Estrogen Replacement Therapy. Tibia / anatomy & histology. Tibia / metabolism
  • [MeSH-minor] Age Factors. Animals. Body Weight. Calcification, Physiologic / drug effects. Calcification, Physiologic / physiology. Female. Macaca fascicularis. Ovariectomy. Random Allocation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15068506.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR14099
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


27. Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J: Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods; 2008 Jul 31;336(2):113-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neutralizing antibodies (NAbs) can occur in some multiple sclerosis (MS) patients receiving interferon beta (IFNbeta) therapy.
  • NAbs reduce drug bioavailabity and high NAb titers reduce drug efficacy.
  • We assayed 163 sera from IFNbeta treated MS patients with an optimized luciferase method and compared the results to those obtained with the reference cytopathic effect (CPE) method using A549 cells and an encephalomyocarditis virus (EMCV).
  • The luciferase assay is reliable, appropriately sensitive and requires less time than the currently available NAb methods.
  • [MeSH-major] Antibodies / blood. Biological Assay / methods. Enzyme-Linked Immunosorbent Assay / methods. Interferon-beta / immunology. Multiple Sclerosis / immunology
  • [MeSH-minor] Cell Line. Cytopathogenic Effect, Viral. Encephalomyocarditis virus / physiology. Genes, Reporter. Humans. Luciferases / genetics. Luciferases / metabolism. Neutralization Tests. Reference Values. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511063.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 77238-31-4 / Interferon-beta; EC 1.13.12.- / Luciferases
  •  go-up   go-down


28. Nepomniashchikh TS, Lebedev LR, Riazankin IA, Pozdniakov SG, Gileeva IP, Shchelkunov SN: [Comparative study of variola virus and monkeypox virus interferon-gamma-binding]. Mol Biol (Mosk); 2005 Nov-Dec;39(6):1055-62
MedlinePlus Health Information. consumer health - Monkeypox Virus Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secreted recombinant IFNgammaBPs were isolated from culture medium of infected Sf21 cells through affinity chromatography procedure.
  • Biological activity of the recombinant IFNgammaBPs were studied in the test of protective effect inhibition of hIFNgamma on L68 cells infected with murine encephalomyocarditis virus.
  • A possibility of the elaboration of new therapeutics for anti-hIFNgamma therapy on the base of IFNgammaBPs is discussed.
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line. Dose-Response Relationship, Drug. Humans. Molecular Sequence Data. Protein Binding. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Recombinant Proteins / pharmacology

  • Genetic Alliance. consumer health - Monkeypox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358743.001).
  • [ISSN] 0026-8984
  • [Journal-full-title] Molekuliarnaia biologiia
  • [ISO-abbreviation] Mol. Biol. (Mosk.)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Recombinant Proteins; 0 / Viral Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


29. Fabrizi F, Colucci P, Ponticelli C, Locatelli F: Kidney and liver involvement in cryoglobulinemia. Semin Nephrol; 2002 Jul;22(4):309-18
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mixed cryoglobulins (MCs) are composed of a polyclonal immunoglobulin G (IgG) bound to another immunoglobulin that acts as an anti-IgG rheumatoid factor; 2 types of MCs can be identified.
  • The great majority (up to 90%) of patients with essential MC (EMC) of both types has been related to HCV infection.
  • A well-characterized pattern of glomerular disease termed "cryoglobulinemic glomerulonephritis" is present in individuals with type-II EMCs in serum and IgMk RF being the most frequent monoclonal component.
  • Aspecific and infrequent glomerular lesions occur in EMC patients with type III cryoglobulins.
  • However, cryoglobulinemic GN may have some distinctive features that differentiate it from idiopathic type-I MPGN.
  • Evidence of liver involvement has been found in 60% to 80% of EMC patients.
  • Recent data support the notion that the stage of liver disease in patients with type II or III MC has association with the prevalence of cryoglobulinemia.
  • Few controlled trials have been published on the treatment of HCV-related MC; in addition, the majority of the patients enrolled in these trials had an unclear renal involvement.
  • Interferon (IFN) is an effective drug for the treatment of patients with HCV-associated MC and cryoglobulinemic GN.
  • In the presence of acute cryoglobulinemic GN, IFN does not prevent progression of renal damage; combination therapy with cytotoxic ad anti-inflammatory drugs, and sometimes plasma exchange, is recommended.
  • [MeSH-minor] Antiviral Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12118396.001).
  • [ISSN] 0270-9295
  • [Journal-full-title] Seminars in nephrology
  • [ISO-abbreviation] Semin. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha
  • [Number-of-references] 61
  •  go-up   go-down


30. Cohen L, Dank G, Milgram J: Non-skeletal multicentric chondrosarcoma in the hindlimb of a dog. J Small Anim Pract; 2010 Oct;51(10):553-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-skeletal multicentric chondrosarcoma in the hindlimb of a dog.
  • Multiple soft tissue masses were palpable within the hindlimb muscles.
  • A tentative diagnosis of sarcoma was made on fine needle aspiration.
  • A computed tomography scan of the hindlimb and thorax confirmed the presence and location of the masses, none of which were associated with the bones of the hindlimb.
  • A diagnosis of chondrosarcoma was confirmed on histopathology with a final diagnosis of extraskeletal chondrosarcoma.
  • A high, hindlimb amputation was performed, and chemotherapy was initiated.
  • [MeSH-major] Bone Neoplasms / veterinary. Chondrosarcoma / veterinary. Dog Diseases / pathology
  • [MeSH-minor] Amputation / veterinary. Animals. Dogs. Female. Hindlimb. Lameness, Animal / pathology. Lameness, Animal / surgery. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 British Small Animal Veterinary Association.
  • (PMID = 21029099.001).
  • [ISSN] 1748-5827
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Schmid B, Warnecke A, Fichtner I, Jung M, Kratz F: Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library. Bioconjug Chem; 2007 Nov-Dec;18(6):1786-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Designing truly tumor-specific prodrugs remains a challenge in the field of cancer chemotherapy.
  • Our screening experiments at pH 7.4 revealed that Met, Leu, and Lys were preferred amino acids in the position P(1) and Tyr, Phe, and Met in P(2), whereas in P(3) and P(4), the cleavage profiles were less characteristic.
  • On the basis of these results, we developed albumin-binding camptothecin (CPT) prodrugs of the general formula EMC-Arg-P(4)-P(3)-P(2)-P(1)-Ala-CPT (EMC = 6-maleimidocaproic acid) that incorporated two peptide linkers: H-Arg-Ala-Phe-Met-OH and H-Arg-Phe-Tyr-Met-OH (P(4)-P(3)-P(2)-P(1)).
  • Incubation studies with homogenates of HT-29 colon tumor tissue and murine spleen, liver, and kidneys demonstrated cleavage of the peptide linker with CPT-peptide derivatives and CPT being the major cleavage products.
  • Although the peptide sequence is not selectively cleaved in colon tumors, an in vivo study in a HT-29 xenograft model showed that the prodrug EMC-Arg-Arg-Ala-Phe-Met-Ala-CPT demonstrated enhanced antitumor efficacy when compared to CPT [( T/ C max: 17% for the prodrug (2 x 12.5 mg/kg CPT equivalents) and 40% for CPT (3 x 12.5 mg/kg)].

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915955.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / Peptide Library; 0 / Prodrugs; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Hartley C, Hartley M, Pardoe I, Knight A: Ionic Contra-Viral Therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch Virol; 2006 Dec;151(12):2495-501
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ionic Contra-Viral Therapy (ICVT); a new approach to the treatment of DNA virus infections.
  • There was normal replication of the RNA virus encephalomyocarditis virus.
  • Antiviral activities of both drugs were influenced by extracellular K(+).
  • Targeting the host cell in this way is fundamentally different to other antiviral drug developments to date and we propose the descriptive term Ionic Contra Viral Therapy (ICVT) for the purpose of definition.
  • [MeSH-major] Antiviral Agents / therapeutic use. DNA Virus Infections / drug therapy. Digoxin / therapeutic use. Furosemide / therapeutic use. Oligonucleotides, Antisense / therapeutic use
  • [MeSH-minor] DNA Viruses / drug effects. DNA Viruses / isolation & purification. Humans. Sodium-Potassium-Exchanging ATPase / antagonists & inhibitors. Sodium-Potassium-Exchanging ATPase / metabolism. Viral Plaque Assay. Virus Replication / drug effects

  • Hazardous Substances Data Bank. DIGOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932984.001).
  • [ISSN] 0304-8608
  • [Journal-full-title] Archives of virology
  • [ISO-abbreviation] Arch. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Oligonucleotides, Antisense; 73K4184T59 / Digoxin; 7LXU5N7ZO5 / Furosemide; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


33. McGrory JE, Rock MG, Nascimento AG, Oliveira AM: Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res; 2001 Jan;(382):185-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal myxoid chondrosarcoma.
  • The medical records and histologic material of 16 patients with extraskeletal myxoid chondrosarcoma were reviewed.
  • Treatment of the primary site included wide excision or amputation in 13 patients and marginal or intralesional resections with radiation in three patients.
  • Local recurrence developed in four, and metastases developed in six of 13 patients presenting with localized disease.
  • Of six patients who received chemotherapy for systemic disease, four had disease progression and died, and two had a response to chemotherapy (one partial, one complete).
  • The current series suggests that extraskeletal myxoid chondrosarcoma is an intermediate-grade neoplasm with a tendency toward recurrence and metastasis.
  • More effective therapy for systemic disease is needed.
  • [MeSH-major] Chondrosarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leg / surgery. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11153986.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Schmid B, Chung DE, Warnecke A, Fichtner I, Kratz F: Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem; 2007 May-Jun;18(3):702-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have recently validated a macromolecular prodrug strategy for improved cancer chemotherapy based on two features: (a) rapid and selective binding of thiol-reactive prodrugs to the cysteine-34 position of endogenous albumin and (b) acid-sensitive promoted or enzymatic release of the drug at the tumor site [Kratz, F., Warnecke, A., Scheuemann, K., Stockmar, C., Schwab, J., Lazar, P., Druckes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderling, C., Folkers, G., Fichtner, I., and Unger, C. (2002) J. Med. Chem.
  • 45, 5523-33]. In the present work, we developed water-soluble camptothecin (CPT) and doxorubicin (DOXO) prodrugs that incorporate the peptide linker Ala-Leu-Ala-Leu that serves as a substrate for the tumor-associated protease, cathepsin B, which is overexpressed in several solid tumors.
  • Consequently, two albumin-binding prodrugs were synthesized [EMC-Arg-Arg-Ala-Leu-Ala-Leu-Ala-CPT (1) and EMC-Arg-Arg-Ala-Leu-Ala-Leu-DOXO (2) (EMC = 6-maleimidocaproic acid)].
  • Major cleavage products were CPT-peptide derivatives and CPT for the CPT prodrug and H-Leu-Ala-Leu-DOXO, H-Leu-DOXO, and DOXO for the doxorubicin prodrug.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cathepsin B / metabolism. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Oligopeptides / metabolism. Oligopeptides / therapeutic use
  • [MeSH-minor] Animals. Humans. Mice. Mice, Inbred Strains. Prodrugs / chemical synthesis. Prodrugs / metabolism. Prodrugs / therapeutic use. Serum Albumin / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378599.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligopeptides; 0 / Prodrugs; 0 / Serum Albumin; 0 / maleimidohexyl-arginyl-arginyl-alanyl-leucyl-alanyl-leucyl-alanyl-camptothecin; 0 / maleimidohexyl-arginyl-arginyl-alanyl-leucyl-alanyl-leucyl-doxorubicin; 80168379AG / Doxorubicin; EC 3.4.22.1 / Cathepsin B; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


35. Kilbourne AM, Reynolds CF 3rd, Good CB, Sereika SM, Justice AC, Fine MJ: How does depression influence diabetes medication adherence in older patients? Am J Geriatr Psychiatry; 2005 Mar;13(3):202-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How does depression influence diabetes medication adherence in older patients?
  • OBJECTIVE: Using various measures (electronic monitoring, patient/provider report, pharmacy data), the authors assessed the association between depression and diabetes medication adherence among older patients with Type 2 diabetes.
  • METHODS: Patients completed a baseline survey on depression (Patient Health Questionnaire) and were given electronic monitoring caps (EMCs) to use with their oral hypoglycemic medication.
  • At the time of the patient baseline survey, providers completed a survey on their patients' overall medication adherence.
  • Upon returning the caps after 30 days, patients completed a survey on their overall medication adherence.
  • EMC adherence was defined as percent of days out of 30 with correct number of doses.
  • Using pharmacy refill data from the patient baseline through 1 year later, they defined adherence as the percentage of days with adequate medication, based on days' supply across refill periods.
  • Depressed patients were less likely to self-report good adherence and had a lower median percentage of days with adequate medication coverage (on the basis of pharmacy refill data).
  • After adjustment for alcohol use, cognitive impairment, age, and other medication use, depression was still negatively associated with adequate adherence, according to patient report and pharmacy data.
  • Depression showed no associated with adherence on the basis of provider or EMC data.
  • CONCLUSIONS: Depression was independently associated with inadequate medication adherence on the basis of patient self-report and pharmacy data.
  • [MeSH-major] Depression / psychology. Diabetes Mellitus, Type 2 / drug therapy. Hypoglycemic Agents / therapeutic use. Patient Compliance / psychology

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15728751.001).
  • [ISSN] 1064-7481
  • [Journal-full-title] The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • [ISO-abbreviation] Am J Geriatr Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypoglycemic Agents
  •  go-up   go-down


36. Kishimoto C, Tomioka N, Nakayama Y, Miyamoto M: Anti-oxidant effects of coenzyme Q10 on experimental viral myocarditis in mice. J Cardiovasc Pharmacol; 2003 Nov;42(5):588-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the effects of coenzyme Q10 (CoQ10) on mice with acute myocarditis inoculated with the encephalomyocarditis (EMC) virus with the analysis of indices of effects of oxidative injury and DNA damage in the myocardium.
  • The mice were injected intraperitoneally 1 day before and daily for 12 days after EMC virus inoculation.
  • In addition, the up-regulation of myocardial thioredoxin with DNA damage, which was induced by the inflammatory stimuli by the virus, was suppressed by the CoQ10 treatment, which may reflect the anti-oxidant effects of CoQ10 treatment.
  • [MeSH-major] Antioxidants / therapeutic use. Myocarditis / drug therapy. Myocarditis / virology. Ubiquinone / analogs & derivatives. Ubiquinone / therapeutic use

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14576505.001).
  • [ISSN] 0160-2446
  • [Journal-full-title] Journal of cardiovascular pharmacology
  • [ISO-abbreviation] J. Cardiovasc. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Coenzymes; 1339-63-5 / Ubiquinone; EJ27X76M46 / coenzyme Q10
  •  go-up   go-down


37. Matsumori A, Shimada M, Jie X, Higuchi H, Groot Kormelink T, Redegeld FA: Effects of free immunoglobulin light chains on viral myocarditis. Circ Res; 2010 May 14;106(9):1533-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We studied the possible involvement of FLC in the pathogenesis of viral myocarditis, and therapeutic effects of FLC using an animal model of viral myocarditis.
  • METHODS AND RESULTS: DBA/2 mice were inoculated intraperitoneally with encephalomyocarditis (EMC) virus.
  • Serum levels and concentrations in the heart of kappa FLC on day 14 in mice inoculated with EMC virus were significantly increased compared with controls.
  • In contrast, an FLC antagonist deteriorated myocarditis. kappa and lambda FLC chains inhibited EMC viral replication in human amnion cells in vitro. lambda FLC significantly increased the gene expression of interleukin-10 in the heart which was previously shown to improve viral myocarditis when given exogenously.
  • FLC may be promising agents for the treatment of viral myocarditis.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Antiviral Agents / pharmacology. Cardiovirus Infections / drug therapy. Immunoglobulin Light Chains / pharmacology. Myocarditis / drug therapy. Myocarditis / virology
  • [MeSH-minor] Animals. Disease Models, Animal. Encephalomyocarditis virus / drug effects. Encephalomyocarditis virus / physiology. Humans. Male. Mice. Mice, Inbred DBA. Microbial Sensitivity Tests. Survival Rate. Virus Replication / drug effects


38. Schellekens H, Geelen G, Meritet JF, Maury C, Tovey MG: Oromucosal interferon therapy: relationship between antiviral activity and viral load. J Interferon Cytokine Res; 2001 Aug;21(8):575-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oromucosal interferon therapy: relationship between antiviral activity and viral load.
  • Intraperitoneal (i.p.) administration of 20,000 IU recombinant murine IFN-alpha (rMuIFN-alpha) was highly effective in protecting mice challenged i.p. with doses of encephalomyocarditis virus (EMCV) ranging from 44 to 440 LD(50) (p<0.001).
  • ) IFN therapy was also found to be effective in protecting mice challenged with a lethal dose of EMCV.
  • Thus, 40% of animals infected with 44 LD(50) of EMCV and treated o.m. with 20,000 IU rMuIFN-alpha survived infection with a mean survival time of 12.0 +/- 2.46 days relative to a mean of 6.11 +/- 0.38 days in the control group (p<0.05).
  • Oromucosal IFN therapy was found to be ineffective, however, in animals infected with higher doses of EMCV (88-440 LD(50)), even though intraperitoneal administration of the same dose of rMuIFN-alpha resulted in the survival of 90%, 50%, and 60% of animals infected with 88, 220, and 440 LD(50) of EMCV, respectively.
  • These results suggest that oromucosal IFN therapy is effective at relatively low viral load only and that the mechanism of action of oromucosal IFN therapy may be different from that of parenterally administered IFN.
  • Our results suggest that oromucosal IFN therapy may be most effective in chronic viral infections as an alternative to parenterally administered IFN, which is clinically effective but poorly tolerated.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cardiovirus Infections / drug therapy. Cardiovirus Infections / virology. Interferon Type I / administration & dosage. Viral Load
  • [MeSH-minor] Administration, Intranasal. Animals. Encephalomyocarditis virus / drug effects. Injections, Intraperitoneal. Lethal Dose 50. Male. Mice. Mouth Mucosa / drug effects. Mouth Mucosa / virology. Oropharynx. Recombinant Proteins. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11559435.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon Type I; 0 / Recombinant Proteins
  •  go-up   go-down


39. Chow WA: Update on chondrosarcomas. Curr Opin Oncol; 2007 Jul;19(4):371-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on chondrosarcomas.
  • PURPOSE OF REVIEW: This paper reviews recent molecular, biologic, developmental therapeutic, and clinical findings in conventional and variant chondrosarcomas.
  • RECENT FINDINGS: The prognosis of chondrosarcomas traditionally correlates with histologic grade and adequacy of surgery.
  • Translational research has validated platelet-derived growth factor receptor, estrogen signaling, matrix metalloproteinase-1, histone deacetylase, methylthioadenosine phosphorylase, and vascular endothelial growth factor-A as potential therapeutic targets.
  • Molecular studies have established that extraskeletal myxoid chondrosarcoma is a unique entity defined by the presence of a fusion gene between the orphan nuclear receptor, CHN/NOR1, and a promiscuous partner, most commonly EWSR1.
  • Clinical studies have shown that development of second malignancies is an uncommon but real risk for chondrosarcoma survivors; the benefit of chemotherapy for dedifferentiated chondrosarcomas remains questionable; and late recurrences of clear cell chondrosarcomas emphasize the need for long-term follow up.
  • SUMMARY: Chondrosarcomas are a heterogeneous group of bone and soft tissue tumors.
  • Recent advances in molecular diagnostics, pathobiology, and developmental therapeutics will aid both scientists and clinicians in improving the classification and therapy of this diverse family of cartilaginous tumors.
  • [MeSH-major] Bone Neoplasms. Chondrosarcoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545802.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


40. Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Stewart AK: Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther; 2001 May;8(5):361-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A murine stem cell virus (MSCV)-based retroviral vector (MSCV-hIL12.B7) utilized distinct IRES sequences from the encephalomyocarditis virus (EMCV) and the foot-and-mouth disease virus (FMCV), whereas Ad5-based adenovirus vectors contained transcriptional units with two EMCV IRES sequences under the control of murine (AdMh12.B7) or human (AdHh12.B7) cytomegalovirus promoters.
  • These results suggest potential clinical utility of AdMh12.B7 in immunotherapy strategies for the treatment of multiple myeloma and other cancers.
  • [MeSH-major] Adenoviridae / genetics. Antigens, CD80 / genetics. Genetic Vectors. Immunotherapy / methods. Interleukin-12 / genetics. Neoplasms / therapy. Retroviridae / genetics. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Cytotoxicity Tests, Immunologic. Cytotoxicity, Immunologic. DNA, Complementary. Drug Therapy, Combination. Flow Cytometry. Gene Transfer Techniques. Humans. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11477456.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / DNA, Complementary; 187348-17-0 / Interleukin-12
  •  go-up   go-down


41. Liu W, Shimada M, Xiao J, Hu D, Matsumori A: Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. Life Sci; 2009 Jul 31;85(5-6):235-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN METHODS: Four-week-old male DBA/2 mice were inoculated with 2 pfu of encephalomyocarditis virus (EMCV) and randomized to nifedipine (n=10) or control (n=10) group.
  • [MeSH-major] Calcium Channel Blockers / pharmacology. Cardiovirus Infections / prevention & control. Encephalomyocarditis virus / physiology. Myocarditis / prevention & control. Nifedipine / pharmacology
  • [MeSH-minor] Animals. Biomarkers / metabolism. Collagen Type I / genetics. Collagen Type I / metabolism. Disease Models, Animal. Gene Expression / drug effects. Heart / drug effects. Heart / virology. Interleukin-5 / genetics. Interleukin-5 / metabolism. Male. Mast Cells / drug effects. Mast Cells / enzymology. Mast Cells / pathology. Matrix Metalloproteinases / genetics. Matrix Metalloproteinases / metabolism. Mice. Mice, Inbred DBA. Myocardium / pathology. Necrosis / drug therapy. Polymerase Chain Reaction. RNA, Messenger / metabolism. Stem Cell Factor / genetics. Stem Cell Factor / metabolism. Tryptases / genetics. Tryptases / metabolism. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19520090.001).
  • [ISSN] 1879-0631
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Calcium Channel Blockers; 0 / Collagen Type I; 0 / Interleukin-5; 0 / RNA, Messenger; 0 / Stem Cell Factor; 0 / Tumor Necrosis Factor-alpha; EC 3.4.21.59 / Tryptases; EC 3.4.24.- / Matrix Metalloproteinases; I9ZF7L6G2L / Nifedipine
  •  go-up   go-down


42. Kato J, Kato N, Moriyama M, Goto T, Taniguchi H, Shiratori Y, Omata M: Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNA-activated protein kinase-independent pathway. J Infect Dis; 2002 Jul 15;186(2):155-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interferon (IFN) therapy is used worldwide as the best available treatment for hepatitis C virus (HCV) infection; however, little is known about how IFN or other drugs work against liver diseases.
  • The effect of 6 drugs (glycyrrhizin, ursodeoxycholic acid, ribavirin, methylprednisolone, IFN-alpha, and IFN-beta) on HCV RNA translation from the HCV internal ribosome entry site (IRES) was investigated, using a bicistronic reporter containing the HCV IRES.
  • In contrast to HCV IRES, IFN did not suppress either foot-and-mouth disease virus IRES-dependent or encephalomyocarditis virus IRES-dependent translation more than it suppressed cap-dependent translation.
  • [MeSH-major] Anti-Infective Agents / pharmacology. Hepacivirus / drug effects. Interferons / pharmacology. Ribosomes / drug effects
  • [MeSH-minor] Antiviral Agents / pharmacology. Autoantigens / biosynthesis. Blotting, Western. Cholagogues and Choleretics / pharmacology. Encephalomyocarditis virus / metabolism. Foot-and-Mouth Disease Virus / metabolism. Glucocorticoids / pharmacology. Glycyrrhizic Acid / pharmacology. Humans. Methylprednisolone / pharmacology. Protein Biosynthesis / drug effects. Protein Biosynthesis / physiology. RNA, Double-Stranded / genetics. RNA, Double-Stranded / metabolism. RNA, Viral / genetics. RNA, Viral / metabolism. Ribavirin / pharmacology. Ribonucleoproteins / biosynthesis. Tumor Cells, Cultured. Ursodeoxycholic Acid / pharmacology

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. GLYCYRRHIZIN .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134250.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antiviral Agents; 0 / Autoantigens; 0 / Cholagogues and Choleretics; 0 / Glucocorticoids; 0 / RNA, Double-Stranded; 0 / RNA, Viral; 0 / Ribonucleoproteins; 0 / SS-B antigen; 49717AWG6K / Ribavirin; 6FO62043WK / Glycyrrhizic Acid; 724L30Y2QR / Ursodeoxycholic Acid; 9008-11-1 / Interferons; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


43. Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT: Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther; 2000 Mar;7(3):486-94
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.
  • Vaccination with cytokine-transduced tumor cells represents a potentially important approach to the treatment of central nervous system tumors.
  • We have recently demonstrated the therapeutic efficacy of tumor cell vaccines expressing the murine interleukin 4 (IL-4) and the herpes simplex virus-thymidine kinase in a rat brain tumor model in which nonirradiated vaccine cells can be eliminated by the subsequent administration of ganciclovir.
  • An MFG-based retroviral vector was used to generate the recombinant retrovirus, TFG-hIL4-Neo-Tk, in which a long terminal repeat-driven polycistronic transcript encodes three cDNAs that are linked and coexpressed using two intervening internal ribosome entry site fragments from the encephalomyocarditis virus.
  • These data demonstrate the suitability of the TFG-hIL4-Neo-Tk vector for therapeutic studies of cytokine-transduced autologous tumor vaccination in patients with malignant gliomas.
  • [MeSH-major] Cancer Vaccines / genetics. Encephalomyocarditis virus / genetics. Genetic Vectors / therapeutic use. Glioma / therapy. Interleukin-4 / genetics. Simplexvirus / genetics. Thymidine Kinase / genetics. Transfection
  • [MeSH-minor] Animals. Cell Line. Ganciclovir / toxicity. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Lymphocyte Activation. Mice. Phorbol Esters / pharmacology. Rats. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10766355.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1KO8-CA70298; United States / NCI NIH HHS / CA / CA68550
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Glial Fibrillary Acidic Protein; 0 / Phorbol Esters; 207137-56-2 / Interleukin-4; 20839-06-9 / phorbol-12-myristate; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


44. Ibrahimi A, Vande Velde G, Reumers V, Toelen J, Thiry I, Vandeputte C, Vets S, Deroose C, Bormans G, Baekelandt V, Debyser Z, Gijsbers R: Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther; 2009 Aug;20(8):845-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gene discovery and gene therapy call for advanced technologies to reliably assess gene expression; efficient coupling of gene expression to the expression of reporter genes is critical.
  • Although the encephalomyocarditis virus (EMCV) IRES yielded functional bicistronic vectors, the expression level of the reporter downstream of IRES was consistently lower than that of the upstream transgene.
  • The intrinsic "cleavage" property of the peptide 2A sequences allows each protein to be produced at proportional levels, opening ample possibilities for functional genomics and future gene therapeutic applications.
  • [MeSH-minor] Amino Acid Sequence. Animals. Blotting, Western. Cell Line. Ganciclovir / pharmacology. Gene Expression Regulation / drug effects. Genes, Reporter. Green Fluorescent Proteins / metabolism. Humans. Mice. Plasmids / genetics. Subcellular Fractions / drug effects. Subcellular Fractions / metabolism. Transduction, Genetic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419274.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


45. Ben-Dor I, Itsykson P, Goldenberg D, Galun E, Reubinoff BE: Lentiviral vectors harboring a dual-gene system allow high and homogeneous transgene expression in selected polyclonal human embryonic stem cells. Mol Ther; 2006 Aug;14(2):255-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic modification of human embryonic stem cells (hESCs) is highly valuable for their exploitation in basic science and therapeutic applications.
  • Here we developed lentiviral vectors (LVs) constitutively expressing a reporter and a selectable marker to enable high and homogeneous transgene expression within polyclonal hESCs.
  • LVs carrying GFP and a downstream puromycin resistance gene, linked by the encephalomyocarditis virus (EMCV) or poliovirus internal ribosome entry sites (IRES), allowed homogeneous GFP expression after antibiotic selection.
  • We also developed dual-promoter vectors harboring a reporter and an antibiotic resistance gene under the regulation of human EF1alpha and PGK1 promoters, respectively.
  • In summary, we developed bicistronic and novel dual-promoter LVs that enable high and homogeneous expression of transgenes by polyclonal hESCs after antibiotic selection.
  • [MeSH-minor] Animals. Cell Line. Cell Line, Tumor. CpG Islands / genetics. Cricetinae. Drug Resistance / genetics. Embryo, Mammalian / cytology. Encephalomyocarditis virus. Green Fluorescent Proteins. Humans. Phenotype. Promoter Regions, Genetic. Puromycin / pharmacology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632408.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS046559-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; 4A6ZS6Q2CL / Puromycin
  •  go-up   go-down


46. Fiehn C, Kratz F, Sass G, Müller-Ladner U, Neumann E: Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis; 2008 Aug;67(8):1188-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis.
  • OBJECTIVE: To examine the effect of an albumin-binding prodrug of methotrexate (MTX) in the treatment of murine collagen-induced arthritis (CIA).
  • METHODS: The prodrug AWO54 with the formula EMC-d-Ala-Phe-Lys-Lys-MTX binds selectively to the cysteine-34 position of endogenous albumin, which acts as a macromolecular drug carrier for MTX to the site of inflammation.
  • The efficacy of the drug was tested in two different stages of CIA: while both, MTX and AWO54 inhibited arthritis in an early stage of the disease, in a later stage only AWO54 showed a significant inhibitory effect in comparison with control.
  • CONCLUSION: Targeted drug delivery by in vivo coupling of a prodrug of MTX to endogenous albumin is better than MTX in the treatment of CIA.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Experimental / drug therapy. Methotrexate / therapeutic use. Prodrugs / therapeutic use
  • [MeSH-minor] Albumins. Animals. Drug Carriers. Mice. Mice, Inbred DBA. Random Allocation. Toxicity Tests, Acute


47. Utsugi T, Yoshida A, Kanda T, Kobayashi I, Kurabayashi M, Tomono S, Kawazu S, Tajima Y, Nagai R: Oral administration of branched chain amino acids improves virus-induced glucose intolerance in mice. Eur J Pharmacol; 2000 Jun 23;398(3):409-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the therapeutic effect of branched chain amino acids (BCAA) on mice with glucose intolerance induced by encephalomyocarditis virus (EMCV).
  • [MeSH-major] Amino Acids, Branched-Chain / therapeutic use. Glucose Intolerance / drug therapy
  • [MeSH-minor] Administration, Oral. Animals. Blood Glucose / drug effects. Cardiovirus Infections. Encephalomyocarditis virus. Male. Mice. Mice, Inbred DBA. Pancreas / drug effects. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10862831.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Amino Acids, Branched-Chain; 0 / Blood Glucose
  •  go-up   go-down


48. Yu F, Chen R, Takahashi T, Sumino H, Morimoto S, Nakahashi T, Iwai K, Matsumoto M, Kanda T: Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Int J Cardiol; 2008 Oct 13;129(3):414-21
Hazardous Substances Data Bank. CANDESARTAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To clarify the mechanism of the effects of angiotensin II receptor type 1 antagonist, candesartan, upon cardiac adiponectin in the combination of myocarditis with obesity, we examined obese KKAy mice with acute viral myocarditis treated by candesartan and investigated cardiac adiponectin regulation.
  • METHODS: Mice were divided into candesartan early treatment group (Can-early) receiving orally candesartan at daily dose of 10 mg/kg 7 days starting before viral inoculation and then 7 days; candesartan late treatment group (Can-late) or vehicle (Vehicle) receiving candesartan starting simultaneously with viral inoculation and then 7 days.
  • Encephalomyocarditis virus was used to induce the acute viral myocarditis.
  • CONCLUSION: Candesartan treatment improved myocardial injury in obese mice with acute viral myocarditis and induced expression of cardiac adiponectin with the induction of C/EBPalpha as well as the reduction of cardiac NF-kappaB and TNF-alpha.
  • [MeSH-major] Adiponectin / biosynthesis. Benzimidazoles / therapeutic use. Cardiovirus Infections / drug therapy. Encephalomyocarditis virus. Myocarditis / drug therapy. Tetrazoles / therapeutic use
  • [MeSH-minor] Animals. Body Weight / drug effects. Body Weight / physiology. Female. Mice. Mice, Obese

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053594.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Benzimidazoles; 0 / Tetrazoles; S8Q36MD2XX / candesartan
  •  go-up   go-down


49. Giangrande PL, Kessler CM, Jenkins CE, Weatherill PJ, Webb PD: Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII. Haemophilia; 2002 Nov;8(6):798-801
SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Porcine factor VIII (FVIII; Hyate:C; Speywood Biopharm Ltd, UK) has been used since 1980 for the treatment both of patients with acquired haemophilia and those with congenital haemophilia and inhibitory antibodies.
  • The production process does not incorporate specific virucidal treatment steps, such as heat treatment or the addition of a solvent/detergent mixture.
  • In this retrospective study, sera from 81 recipients of porcine FVIII and 125 other volunteers were screened for evidence of antibodies against a range of porcine viruses: porcine parvovirus (PPV), encephalomyocarditis virus (EMCV), and porcine respiratory and reproductive syndrome virus (PRRSV).
  • [MeSH-major] Drug Contamination. Factor VIII / therapeutic use. Hemophilia A / drug therapy. Parvoviridae / isolation & purification

  • MedlinePlus Health Information. consumer health - Hemophilia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12410650.001).
  • [ISSN] 1351-8216
  • [Journal-full-title] Haemophilia : the official journal of the World Federation of Hemophilia
  • [ISO-abbreviation] Haemophilia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 9001-27-8 / Factor VIII
  •  go-up   go-down


50. Ito H, Ono K, Nishio R, Sasayama S, Matsumori A: Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice. Cytokine; 2002 Feb 21;17(4):197-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was performed to examine the effects of amiodarone on survival, heart weight-to-body-weight ratio (HW/BW), myocardial lesions and cytokines production in a murine model of viral myocarditis induced by the encephalomyocarditis virus (EMCV).
  • This study suggests that the beneficial effects of amiodarone in viral myocarditis may be mediated by decreasing interleukin 6 production in myocardial tissue.
  • [MeSH-major] Amiodarone / therapeutic use. Cardiovirus Infections / drug therapy. Encephalomyocarditis virus. Heart Failure / drug therapy. Interleukin-6 / biosynthesis. Myocarditis / drug therapy. Myocardium / pathology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ltd. All rights reserved.
  • (PMID = 11991672.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; N3RQ532IUT / Amiodarone
  •  go-up   go-down


51. Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Abu Ajaj K, Unger C, Warnecke A, Saleem T, El-Melegy N, Madkor H, Kratz F: Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer; 2010 Dec;46(18):3434-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In developed countries, prostate cancer is the third most common cause of death from cancer in men.
  • Unfortunately, whilst accumulating clinical data have suggested that taxanes may prolong the survival in a subset of men with prostate carcinoma, the dose and duration of administration of these drugs are limited by their significant systemic toxicities due to a lack of tumour selectivity.
  • In an attempt to improve both the water solubility and tumour-targeting properties of paclitaxel (Taxol®), we set out to develop a water soluble paclitaxel prodrug that is activated specifically by prostate-specific antigen (PSA) which is almost exclusively expressed in prostate tissue and prostate carcinoma making it an ideal molecular target for prodrug strategies.
  • Using albumin as a drug carrier, we describe a novel albumin-binding prodrug of paclitaxel, EMC-Arg-Ser-Ser-Tyr-Tyr-Ser-Leu-PABC-paclitaxel [EMC: ε-maleimidocaproyl; PABC: p-aminobenzyloxycarbonyl] that was synthesised by reacting EMC-Arg-Ser-Ser-Tyr-Tyr-Ser-OH with H-Leu-PABC-paclitaxel.
  • Last but not least, due to the incorporation of a PABC self-eliminating linker, this dipeptide was rapidly degraded to liberate paclitaxel as a final cleavage product within a few hours in prostate tumour tissue homogenates.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Prodrugs / therapeutic use. Prostate-Specific Antigen / physiology. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Drug Evaluation. Humans. Luminescence. Male. Maximum Tolerated Dose. Mice. Mice, SCID. Neoplasm Transplantation. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20933385.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Prodrugs; EC 3.4.21.77 / Prostate-Specific Antigen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


52. Scagnolari C, Casato M, Bellomi F, De Pisa F, Turriziani O, Coviello R, Pirro MR, Dianzani F, Antonelli G: Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol; 2003 Jan;10(1):70-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.
  • The efficacy of alpha interferon (IFN-alpha) in the treatment of severe type II essential mixed cryoglobulinemia (EMC) has been reported previously.
  • In some patients, the development of neutralizing antibodies to recombinant IFN-alpha (rIFN-alpha) can affect the clinical response achieved with rIFN-alpha; a second treatment with natural IFN-alpha preparations may reinduce the clinical response.
  • Specifically, the pharmacodynamic profiles of different IFN-alpha preparations were studied by measuring the serum neopterin levels and the levels of expression of protein MxA mRNA in in vivo peripheral blood mononuclear cells in two patients with EMC whose resistance to rIFN-alpha2a treatment increased concomitantly with the development of neutralizing antibodies.
  • Sera from these patients neutralized most but not all of the subtypes present in the natural IFN-alpha (LeIFN) mixture, and no significant increase in neopterin levels was observed after these patients were switched to LeIFN treatment.
  • In summary, the data demonstrate that the problem of neutralizing antibodies still exists and that LeIFN may induce an increase in the level of MxA mRNA expression but not an increase in neopterin levels in patients who are resistant to treatment with rIFN-alpha2a or (C)IFN.
  • [MeSH-major] Cryoglobulinemia / drug therapy. Interferon-alpha / immunology. Interferon-alpha / therapeutic use
  • [MeSH-minor] Antibodies / blood. Biomarkers / blood. Female. GTP-Binding Proteins / genetics. Humans. Leukocytes / chemistry. Male. Middle Aged. Myxovirus Resistance Proteins. Neopterin / blood. RNA, Messenger / analysis. Recombinant Proteins / immunology. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 2000 Oct;81(Pt 10):2341-64 [10993923.001]
  • [Cites] J Hepatol. 1992 Mar;14(2-3):419-20 [1500709.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):4984-90 [2944575.001]
  • [Cites] Methods Enzymol. 1986;119:558-73 [2429157.001]
  • [Cites] N Engl J Med. 1988 Jun 2;318(22):1409-13 [3367950.001]
  • [Cites] Blut. 1988 Nov;57(5):311-5 [3196882.001]
  • [Cites] Clin Exp Immunol. 1992 Sep;89(3):330-5 [1516252.001]
  • [Cites] Neurology. 1993 Apr;43(4):655-61 [8469318.001]
  • [Cites] Leuk Lymphoma. 1993;11 Suppl 1:193-7 [8251895.001]
  • [Cites] Br J Haematol. 1994 Jan;86(1):216-8 [8011536.001]
  • [Cites] J Hepatol. 1994 Mar;20(3):416-20 [7516951.001]
  • [Cites] Clin Exp Immunol. 1994 Jul;97(1):4-9 [8033418.001]
  • [Cites] Eur J Cancer. 1994;30A(11):1729-30 [7833154.001]
  • [Cites] J Biol Regul Homeost Agents. 1994 Apr-Jun;8(2):56-9 [7863814.001]
  • [Cites] Hepatogastroenterology. 1995 Jul;42(3):201-4 [7590565.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):300-5 [8759890.001]
  • [Cites] J Interferon Cytokine Res. 1996 Jul;16(7):489-99 [8836913.001]
  • [Cites] Neurology. 1996 Oct;47(4):889-94 [8857714.001]
  • [Cites] J Interferon Cytokine Res. 1996 Dec;16(12):1027-33 [8974005.001]
  • [Cites] J Immunother. 1997 May;20(3):208-13 [9181459.001]
  • [Cites] J Interferon Cytokine Res. 1997 Jul;17 Suppl 1:S39-46 [9241615.001]
  • [Cites] Biotherapy. 1997;10(1):93-8 [9261553.001]
  • [Cites] N Engl J Med. 1998 May 7;338(19):1386-7 [9575053.001]
  • [Cites] Neurology. 1998 May;50(5):1266-72 [9595973.001]
  • [Cites] J Interferon Cytokine Res. 1998 May;18(5):345-50 [9620362.001]
  • [Cites] J Interferon Cytokine Res. 1999 Mar;19(3):243-51 [10213463.001]
  • [Cites] Neurology. 1999 Apr 12;52(6):1239-43 [10214750.001]
  • [Cites] Nephrol Dial Transplant. 1999 Jun;14(6):1558-60 [10383026.001]
  • [Cites] Exp Dermatol. 1999 Jun;8(3):167-76 [10389633.001]
  • [Cites] J Interferon Cytokine Res. 2001 Oct;21(10):835-41 [11710996.001]
  • [Cites] Neurology. 2001 Sep 25;57(6):1080-4 [11571337.001]
  • [Cites] Gut. 2002 Feb;50(2):191-5 [11788558.001]
  • [Cites] Arch Biochem Biophys. 1981 Aug;210(1):319-29 [6170263.001]
  • [Cites] Biochem Biophys Res Commun. 1983 Apr 29;112(2):537-46 [6303322.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Aug;81(15):4926-9 [6589637.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 5;81(7):531-5 [2466128.001]
  • [Cites] J Chromatogr. 1988 Nov 11;454:205-15 [3235597.001]
  • [Cites] Eur J Haematol Suppl. 1990;52:7-8 [2279546.001]
  • [Cites] J Infect Dis. 1991 Apr;163(4):882-5 [1901335.001]
  • [Cites] Blood. 1991 Jul 1;78(1):38-43 [2070058.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3142-7 [1742481.001]
  • [Cites] J Interferon Res. 1992 Feb;12(1):55-9 [1573283.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):612-4 [11232730.001]
  • (PMID = 12522042.001).
  • [ISSN] 1071-412X
  • [Journal-full-title] Clinical and diagnostic laboratory immunology
  • [ISO-abbreviation] Clin. Diagn. Lab. Immunol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers; 0 / Interferon-alpha; 0 / MX1 protein, human; 0 / Myxovirus Resistance Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 670-65-5 / Neopterin; EC 3.6.1.- / GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC145266
  •  go-up   go-down


53. François C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, Gatignol A, Wychowski C, Moradpour D, Meurs EF: Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol; 2000 Jun;74(12):5587-96
Hazardous Substances Data Bank. TETRACYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatitis C virus (HCV) of genotype 1 is the most resistant to interferon (IFN) therapy.
  • IFN-treated, induced UHCV cells were found to better support the growth of encephalomyocarditis virus (EMCV) than IFN-treated, uninduced cells.
  • The effect of expression of HCV proteins on PKR activity was assayed in a reporter assay and by direct analysis of the in vivo phosphorylation of eIF2alpha after treatment of cells with poly(I)-poly(C).
  • [MeSH-minor] 2',5'-Oligoadenylate Synthetase / biosynthesis. 2',5'-Oligoadenylate Synthetase / metabolism. Cytoplasm / chemistry. Cytoplasm / enzymology. Encephalomyocarditis virus / drug effects. Encephalomyocarditis virus / physiology. Endoplasmic Reticulum / chemistry. Eukaryotic Initiation Factor-2 / metabolism. Gene Expression / drug effects. Gene Expression Regulation, Viral / drug effects. Humans. Microscopy, Confocal. Phosphorylation / drug effects. Poly I-C / pharmacology. Polyproteins / biosynthesis. Polyproteins / genetics. Polyproteins / metabolism. Protein Biosynthesis / drug effects. Tetracycline / pharmacology. Tumor Cells, Cultured. Viral Nonstructural Proteins / biosynthesis. Viral Nonstructural Proteins / genetics. Viral Nonstructural Proteins / metabolism

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1993 Aug;67(8):4760-8 [8392613.001]
  • [Cites] J Virol. 1999 Oct;73(10):8469-75 [10482599.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1058-9 [7723533.001]
  • [Cites] Exp Cell Res. 1995 May;218(1):17-27 [7737357.001]
  • [Cites] J Virol. 1995 Jun;69(6):3904-9 [7745744.001]
  • [Cites] J Biol Chem. 1995 Jul 21;270(29):17423-8 [7615547.001]
  • [Cites] N Engl J Med. 1996 Jan 11;334(2):77-81 [8531962.001]
  • [Cites] Virology. 1995 Dec 20;214(2):653-9 [8553571.001]
  • [Cites] Gene Expr. 1996;5(4-5):217-28 [8723388.001]
  • [Cites] EMBO J. 1997 Feb 3;16(3):611-24 [9034343.001]
  • [Cites] Hepatology. 1997 Mar;25(3):740-4 [9049228.001]
  • [Cites] Virology. 1997 Apr 14;230(2):217-27 [9143277.001]
  • [Cites] Hepatology. 1997 Jun;25(6):1527-38 [9185778.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):567-72 [9247477.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):72-7 [9252076.001]
  • [Cites] J Interferon Cytokine Res. 1997 Sep;17(9):503-24 [9335428.001]
  • [Cites] J Med Virol. 1997 Oct;53(2):118-26 [9334922.001]
  • [Cites] Hepatology. 1999 Apr;29(4):1262-71 [10094974.001]
  • [Cites] J Gen Virol. 1999 Apr;80 ( Pt 4):879-86 [10211956.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jul;82(13):4341-5 [3859866.001]
  • [Cites] Virology. 1987 Jul;159(1):126-36 [2440179.001]
  • [Cites] Eur J Biochem. 1987 Sep 15;167(3):467-73 [3653103.001]
  • [Cites] Nature. 1987 Dec 10-16;330(6148):587-8 [2825034.001]
  • [Cites] J Biol Chem. 1988 Apr 5;263(10):4945-9 [3350819.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5974-8 [2762307.001]
  • [Cites] J Virol. 1990 Jul;64(7):3370-5 [2161946.001]
  • [Cites] Virology. 1990 Nov;179(1):228-33 [2171206.001]
  • [Cites] J Virol. 1991 Feb;65(2):632-40 [1702840.001]
  • [Cites] Science. 1991 Mar 29;251(5001):1597-600 [2011739.001]
  • [Cites] Annu Rev Biochem. 1991;60:717-55 [1883206.001]
  • [Cites] EMBO J. 1992 Apr;11(4):1553-62 [1348691.001]
  • [Cites] J Virol. 1992 Oct;66(10):5805-14 [1382142.001]
  • [Cites] Science. 1992 Sep 18;257(5077):1685-9 [1382315.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):232-6 [7678339.001]
  • [Cites] Eur J Biochem. 1997 Sep 1;248(2):558-66 [9346316.001]
  • [Cites] J Virol. 1998 Feb;72(2):1516-22 [9445055.001]
  • [Cites] Exp Cell Res. 1998 Mar 15;239(2):379-92 [9521856.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1373-81 [9634077.001]
  • [Cites] Hepatology. 1998 Jul;28(1):192-201 [9657112.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5208-18 [9710605.001]
  • [Cites] Virology. 1999 Mar 30;256(1):8-14 [10087221.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5533-8 [10318918.001]
  • [Cites] Virology. 1999 Jun 5;258(2):435-40 [10366581.001]
  • [Cites] Science. 1999 Jul 2;285(5424):107-10 [10390359.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18593-8 [7518438.001]
  • (PMID = 10823866.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Eukaryotic Initiation Factor-2; 0 / NS-5 protein, hepatitis C virus; 0 / Polyproteins; 0 / Viral Nonstructural Proteins; 0 / Viral Proteins; 24939-03-5 / Poly I-C; 9008-11-1 / Interferons; EC 2.7.11.1 / eIF-2 Kinase; EC 2.7.7.- / 2',5'-Oligoadenylate Synthetase; F8VB5M810T / Tetracycline
  • [Other-IDs] NLM/ PMC112046
  •  go-up   go-down


54. Wang JF, Meissner A, Malek S, Chen Y, Ke Q, Zhang J, Chu V, Hampton TG, Crumpacker CS, Abelmann WH, Amende I, Morgan JP: Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol; 2005 Oct;289(4):H1577-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BALB/c mice were inoculated with the encephalomyocarditis virus (EMCV) or sham inoculated with saline and followed for 30 days.
  • Treatment with the beta-blocker propranolol significantly decreased mortality, myocardial necrosis, and infiltration of inflammatory cells in EMCV-inoculated mice.
  • [MeSH-major] Adrenergic Agonists / pharmacology. Adrenergic beta-Antagonists / pharmacology. Cardiovirus Infections / drug therapy. Encephalomyocarditis virus. Epinephrine / pharmacology. Myocarditis / drug therapy. Propranolol / pharmacology

  • Genetic Alliance. consumer health - Myocarditis.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923319.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA-12774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic Agonists; 0 / Adrenergic beta-Antagonists; 0 / Cytokines; 9Y8NXQ24VQ / Propranolol; YKH834O4BH / Epinephrine
  •  go-up   go-down


55. Matsumori A, Nunokawa Y, Yamaki A, Yamamoto K, Hwang MW, Miyamoto T, Hara M, Nishio R, Kitaura-Inenaga K, Ono K: Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappaB inhibitor. Eur J Heart Fail; 2004 Mar 1;6(2):137-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to protecting mice against lethal endotoxemia, SUN C8079 prevented the development of myocarditis due to the encephalomyocarditis virus (EMCV), and inhibited the expressions of proinflammatory cytokines and the iNOS gene in cardiac tissues.
  • CONCLUSION: These findings suggest that the activation of NF-kappaB plays an important role in the pathogenesis of endotoxemia and viral myocarditis, and that the NF-kappaB inhibitor, SUN C8079, may be therapeutic in these disorders.
  • [MeSH-minor] Animals. Cardiovirus Infections / drug therapy. Cardiovirus Infections / prevention & control. Cardiovirus Infections / virology. Cell Nucleus / metabolism. Cells, Cultured. DNA, Complementary / metabolism. Encephalomyocarditis virus. Female. Gene Expression Regulation / drug effects. Humans. In Vitro Techniques. Interleukin-1 / biosynthesis. Interleukin-1 / genetics. Lipopolysaccharides / toxicity. Male. Mice. Mice, Inbred BALB C. Mice, Inbred DBA. Nitric Oxide Synthase Type II. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Myocarditis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984720.001).
  • [ISSN] 1388-9842
  • [Journal-full-title] European journal of heart failure
  • [ISO-abbreviation] Eur. J. Heart Fail.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Interleukin-1; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Piperidines; 0 / RNA, Messenger; 0 / SUN C8079; 0 / Tumor Necrosis Factor-alpha; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, mouse
  •  go-up   go-down


56. Hiraoka Y, Kishimoto C, Takada H, Ochiai H: Oral administration of L-arginine prevents congestive heart failure in murine viral myocarditis. J Cardiovasc Pharmacol; 2002 Jul;40(1):1-8
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary l-arginine and l-arginine plus l-NAME (l-arginine + l-NAME group) were administered to encephalomyocarditis virus-infected BALB/c mice over 4 weeks (experiment I) and to encephalomyocarditis virus-infected DBA/2 mice from the 4th through 12th weeks after the virus inoculation (experiment II).
  • In experiment II, plasma cardiomyopathic lesions in the l-arginine group were less prominent and were associated with lower plasma catecholamine and lower myocardial collagen concentrations compared with the other two groups. l-arginine treatment may be effective in preventing the development of CHF in viral myocarditis by modifying postmyocarditic architectural remodeling.
  • [MeSH-major] Arginine / administration & dosage. Cardiovirus Infections / drug therapy. Encephalomyocarditis virus / drug effects. Heart Failure / prevention & control. Myocarditis / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12072571.001).
  • [ISSN] 0160-2446
  • [Journal-full-title] Journal of cardiovascular pharmacology
  • [ISO-abbreviation] J. Cardiovasc. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 94ZLA3W45F / Arginine
  •  go-up   go-down


57. Miyamoto T, Matsumori A, Hwang MW, Nishio R, Ito H, Sasayama S: Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol; 2001 May;37(6):1713-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis.
  • OBJECTIVES: This study examines the efficacy of FTY720 (FTY), a new immunosuppressor, in the treatment of acute viral myocarditis in a murine model.
  • BACKGROUND: Immunosuppressive agents have no proven therapeutic efficacy in experimental or clinical myocarditis.
  • METHODS: Encephalomyocarditis virus was inoculated i.p. in DBA/2 mice on day 0.
  • Postinoculation treatment consisted of FTY 10 mg/kg/day p.o. (FTY group), or cyclosporine A (CsA) 40 mg/kg/day p.o. (CsA group) or distilled water p.o. only (control group).
  • CONCLUSIONS: FTY720 had a significant therapeutic effect in acute experimental myocarditis without inducing excessive virus replication.
  • This report is the first to describe a beneficial effect by an immunosuppressive agent in the treatment of acute viral myocarditis.
  • [MeSH-major] Cardiovirus Infections / complications. Disease Models, Animal. Encephalomyocarditis virus. Immunosuppressive Agents / therapeutic use. Myocarditis / drug therapy. Myocarditis / virology. Propylene Glycols / therapeutic use
  • [MeSH-minor] Acute Disease. Animals. Drug Evaluation, Preclinical. Fingolimod Hydrochloride. Humans. Interferon-gamma / analysis. Interleukin-12 / analysis. Interleukin-2 / analysis. Male. Mice. Mice, Inbred DBA. Nitric Oxide / analysis. Proportional Hazards Models. Severity of Illness Index. Sphingosine / analogs & derivatives. Survival Analysis. Treatment Outcome. Tumor Necrosis Factor-alpha / analysis

  • Genetic Alliance. consumer health - Myocarditis.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11345389.001).
  • [ISSN] 0735-1097
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Propylene Glycols; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12; 31C4KY9ESH / Nitric Oxide; 82115-62-6 / Interferon-gamma; G926EC510T / Fingolimod Hydrochloride; NGZ37HRE42 / Sphingosine
  •  go-up   go-down


58. Saegusa S, Fei Y, Takahashi T, Sumino H, Moriya J, Kawaura K, Yamakawa J, Itoh T, Morimoto S, Nakahashi T, Iwai K, Matsumoto M, Kanda T: Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther; 2007 Jun;21(3):155-60
Hazardous Substances Data Bank. CANDESARTAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We examined the effects of the angiotensin II receptor type 1 blocker candesartan on myocarditis injury in a murine model of acute myocarditis.
  • We intraperitoneally injected encephalomyocarditis virus in C3H mice, then orally administered candesartan (10 mg/kg/day) or vehicle (control).

  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484035.001).
  • [ISSN] 0920-3206
  • [Journal-full-title] Cardiovascular drugs and therapy
  • [ISO-abbreviation] Cardiovasc Drugs Ther
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Benzimidazoles; 0 / RNA, Messenger; 0 / Tetrazoles; 0 / Tumor Necrosis Factor-alpha; S8Q36MD2XX / candesartan
  •  go-up   go-down






Advertisement